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Abstract 
Multiple sclerosis is an immune mediated disease effecting the central nervous 
system, characterized by inflammatory infiltrates, axonal loss, demyelination 
and plaque formation. The invasion of the central nervous system by inflamma-
tory auto-reactive lymphocytes leads to an inflammatory effector phase. Multiple 
sclerosis is documented as a major cause of neurological disability in young 
populations affecting more than 2.5 million people around the world. Still to 
date, the cause of multiple sclerosis is not yet fully elucidated, considerable 
knowledge about its pathophysiology has been studied. In addition to that, 
there’s no cure present for this devastating condition despite the availability of 
several disease-modifying treatments. These drugs have been reported to re-
duce the number of relapses, but unfortunately none of these treatments can 
completely protect against disease progression. Adding to that, many of the 
disease-modifying therapies used to treat multiple sclerosis hold major health 
risks, such as cardiotoxicity, liver damage and progressive multifocal leu-
koencephalopathy. Therefore, identification of novel targets and the develop-
ment of new therapeutic options are crucial steps for the treatment of multiple 
sclerosis patients.  
In this study, we investigated the role of the acid sphingomyelinase/ceramide 
pathway in two animal models of multiple sclerosis. Using the chronic experi-
mental autoimmune encephalomyelitis model we demonstrate that both genetic 
deficiency and the pharmacological inhibition of acid sphingomyelinase by ami-
triptyline inhibit the infiltration of lymphocytes to the central nervous system and 
abolish clinical symptoms, with a decreased astrogliosis and microgliosis. 
Sphingolipids, in particular ceramide, and the enzyme acid sphingomyelinase, 
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which generates ceramide from sphingomyelin, seem to be involved in lympho-
cyte infiltration to the central nervous system.  
The second model, the toxic demyelination model or as called the cuprizone 
model was employed to study central nervous demyelination without the direct 
immunological influence observed in the experimental autoimmune encephalo-
myelitis model. We demonstrate that mice lacking the enzyme acid sphingo-
myelinase show a significantly higher/faster myelin recovery after acute or 
chronic myelin damage by enhancement of oligodendrocyte proliferation, de-
creased astroglial activation and axonal damage. Inhibition of acid sphingomye-
linase using the drug amitriptyline mimicked the genetic deficiency effects and 
may constitute a novel therapeutic approach to prevent chronic degeneration in 
multiple sclerosis. 
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Zusammenfassung 
Multiple Sklerose ist eine chronisch entzündliche Erkrankung des zentralen 
Nervensystems, gekennzeichnet durch entzündliche Infiltrate, axonalen Verlust, 
Demyelinisierung und Plaquebildung. Die Invasion des Zentralnervensystems 
durch entzündliche autoreaktive Lymphozyten führt zu einer Kaskade 
entzündlicher Reaktionen. Multiple Sklerose ist die häufigste Ursache für 
neurologische Behinderung bei jungen Erwachsenen mit mehr als 2,5 Millionen 
Menschen weltweit. Noch immer ist die Ursache der Multiplen Sklerose trotz 
umfangreichem Wissen über ihre Pathophysiologie noch nicht vollständig 
aufgeklärt. Darüber hinaus gibt es zum heutigen Zeitpunkt kein Heilung für 
Multiple Sklerose, trotz der Verfügbarkeit von mehreren krankheitsverändernde 
Behandlungen, einschließlich Interferonen, Mitoxantron und FTY720. Diese 
Medikamente haben gezeigt, dass die Anzahl der Schübe reduzierbar ist, aber 
leider können keine dieser Behandlungen vollständig vor dem Fortschreiten der 
Krankheit schützen. Hinzu kommt, dass viele der krankheitsmodifizierenden 
Therapien, die zur Behandlung von Multipler Sklerose eingesetzt werden, 
erhebliche Gesundheitsrisiken wie Kardiotoxizität, Leberschädigung und 
progressive multifokale Leukoenzephalopathie mit sich bringen können. Daher 
sind die Identifizierung neuer Ziele und die Entwicklung neuer Therapieoptionen 
entscheidende Schritte zur Behandlung von Patienten mit Multipler Sklerose. 
In dieser Studie untersuchten wir die Rolle des sauren Sphingomyelinase / 
Ceramid Systems in zwei Tiermodellen der Multiple Sklerose. Unter 
Verwendung des chronischen experimentellen Autoimmun-Enzephalomyelitis-
Modells zeigten wir, dass sowohl der genetische Mangel als auch die 
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pharmakologische Hemmung der sauren Sphingomyelinase durch Amitriptylin 
die Infiltration von Lymphozyten in das zentrale Nervensystem hemmen und die 
klinischen Symptome mit einer verminderten Astrogliose und Mikrogliose 
beseitigen kann. Sphingolipide, insbesondere Ceramide, und das Enzym saure 
Sphingomyelinase, das Ceramid aus Sphingomyelin erzeugen kann, und 
infiltration von Lymphozyten in das zentrale Nervensystem beteiligt zu sein. 
Diese Ergebnisse entsprechen früheren Berichten, die die Beziehung von 
Ceramid-angereicherten Membranplattformen bei der Signalamplifikation und 
neuronaler Schädigung bei Multipler Sklerose zeigen. 
Das zweite Modell, das toxische Demyelinisierung Modell oder das sogenannte 
Cuprizonmodell, wurde verwendet, um die zentrale nervöse Demyelinisierung 
ohne den direkten immunologischen Einfluss zu untersuchen, der in dem 
experimentellen Autoimmun-Enzephalomyelitis-Modell beobachtet wurde. Wir 
zeigen, dass Mäuse, denen die sauren Sphingomyelinase fehlt, nach einer 
akuten oder chronischen Myelinschädigung durch Verstärkung der 
Oligodendrozytenproliferation, verminderter astroglialer Aktivierung und 
axonaler Schädigung einen signifikanten Anstieg der Remyelinisierung zeigen. 
Die Hemmung der sauren Sphingomyelinase unter Verwendung des 
Medikaments Amitriptylin imitiert die Auswirkung des genetischen Mangels und 
kann einen neuen therapeutischen Ansatz darstellen, um eine chronische 
Degeneration bei Multipler Sklerose zu verhindern. 
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1. Introduction 
 Multiple Sclerosis: overview  
 
Multiple Sclerosis (MS) is a demyelinating disease which often described as an 
autoimmune disease of the central nervous system (CNS). Unfolded initially in 
1838, today MS is recognized worldwide affecting more than 2.5 million individ-
uals. With its wide distribution, MS is widely spread among young adults world 
wide causing major neurological disabilities. It is documented that MS is affect-
ing women more often as men (Sospedra and Martin 2005; Pugliatti et al., 
2006). MS is categorized to four subtypes; relapsing-remitting (RR), secondary-
progressive (SP), primary-progressive (PP), and progressive-relapsing (PR) – 
according to the clinical course of the disease (Lubin and Reingold, 1996). Most 
MS patients have a relapsing-remitting (RRMS) subtype, where a full recovery 
between relapses could be observed. But with time these patients do not recov-
er fully between relapses and develop a secondary-progressive (SP) form of 
MS (Compston et al., 2006). The less common form of MS which 15% of pa-
tients develop is a primary-progressive (PPMS) characterized by a continuous 
worsening in neurological functions (Lubin et al., 1996; Miller et al., 2007). To-
day the diagnose of MS is based on clinical symptoms and MRI featrues, which   
physicians evaluate using an evolving set of criteria, called the McDonald Crite-
ria (Polman et al., 2011). 
 MS epidemiology  
 
The diagnosis of MS has increased with a 0.7-8.7 per 100,000/year and a prev-
alence of 1-287 per 100,000 people (Rosati, 2001). MS distribution varies with 
geographic latitude <5 cases per 100,000 people in Asia and >100-200 cases 
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per 100,000 people including northern Europe. Also, as mentioned by Charcot 
and others the prevalence of females with MS worldwide is double as of males 
with a ratio 2:1, specifically Canada where the female/male ratio is 3:1 (Comp-
ston et al., 2006). 
 MS etiology 
 
The etiology of MS is still unknown to this date, but most of the research done is 
pointing toward the involvement of three major factors. The genetic vulnerability, 
several studies are being carried out in an effort to identify associated risk and 
susceptibility genes, protection and disease severity genes (Haines et al., 
1996). Environmental exposures are considered as a second factor; both vita-
min D deficiency and Epstein-Barr virus (EBV) infection have been related to 
MS development. The third factor is the host immune system, attacking and 
destroying the CNS, hence MS is considered as an autoimmune disease (Bar-
net et al., 2009; Syed and Rizvi et al., 2011). 
 MS pathophysiology 
 
Histopathological hallmarks of MS consist of inflammatory plaques with the infil-
tration of T cells, B cells, and macrophages, glial scar formation, loss of oli-
godendrocytes, myelin break down, and axonal damage/loss, which is the major 
factor causing irreversible damage in patients with MS (Lassmann et al., 2001). 
In MS several events are well documented such as; the breakdown of the 
blood-brain barrier (BBB), infiltration of T cells attacking the myelin leading to 
axonal damage, formation of lesions referred to as plaques accompanied with 
focal inflammation as shown in figure one.  
Sphingolipids in MS 
 
11 
 
Recovery and remyelination is a highly complex process. The formation of glial 
scars consisting of reactive astrocytes can be observed, which in turn prevents 
in most cases a normal remyelination process. Astrocytes are documented to 
activate migrolia indirectly to engulf myelin debris. To make a way for new oli-
godendrocyte precursor cells to remyelinate the damaged area. Therefore, as-
trocytes are reported to play a dual role in de- and remyelination (Trap et al., 
2008; Syed and Rizvi., 2011).  
 
Figure 1: MRI abnormalities in relapsing–remitting multiple sclerosis. Scars can be de-
tected affecting the cerebrum (i), optic nerve (ii), (iii) cerebellar peduncle (iv), and spinal 
cord (v) (Compston et al., 2006). 
 
The phagocytosis of myelin is primarily not a CD4+ T cell mediated process; it 
represents the macrophage`s natural response to injury (Henderson et al., 
2009). On the other hand, CD4+ and CD8+ T cells are distributed along demye-
linated tissues, with B cells and, occasionally regenerating oligodendrocytes. 
Sphingolipids in MS 
 
12 
 
Active plaques are characterized by the presence of partly demyelinated axons 
and macrophages filled with myelin debris (Prineas et al., 2002).  Plaques pa-
thology involves edema and inflammation, myelin loss, oligodendrocyte apopto-
sis, astrocyte and microglia activation which in turn results in the releasing of 
several chemokines and cytokines such as interleukin-1 (IL-1); IL-2; tumor ne-
crosis factor (TNF); interferon-ɣ (IFNɣ). With time cells are cleared and a per-
manent area of damage surrounded by an astrocytic scar appears (Syed and 
Rizvi et al., 2011). 
 Animal models of MS 
 
Experimental Autoimmune Encephalomyelitis (EAE), which was developed in 
1933 (Rivers et al., 1933) it is one of the widely used models. It is achieved by 
immunizing with myelin oligodendrocyte glycoprotein (MOG), myelin basic pro-
tein (MBP), or proteolipid protein (PLP). In EAE, CD4+ and CD8+ T cells and 
humoral immune responses play a role. MOG-induced EAE perhaps mimcs the 
most of what we see in MS patients, however, no EAE model could one hun-
dred percent dublicate MS.  
For de- and remyelination several animal models exist; genetic myelin mutation, 
EAE, viral induced demyelination (e.g. Theiler’s Murine Encephalomyelitis virus, 
TMEV) an infectious animal model, causing a polioencephalomyelitis in mice, 
followed by an inflammatory demyelinating spinal cord infection (Sato et al., 
2010; Gudi 2010), and toxically induced demyelination (e.g. cuprizone, ethidium 
bromide, or lysolecithin), as demostrated in figure 2. All these models mimic 
only a part of MS pathology (Olitsky and Yager, 1949; Gold et al., 2000; Gudi 
2010).  
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Figure 2: Experimental animal models of MS. Different animal models of MS used for 
different research purposes. 
 
The cuprizone model is a widely used model. Mice are fed with the copper che-
lator cuprizone (bis-cyclohexanone oxaldihydrazone) for several weeks leading 
to a loss of oligodendrocytes and a subsequent demyelination accompanied by 
microgliosis and astrogliosis. After withdrawal of the toxin, remyelination occurs 
within weeks (Hiremath et al., 1998; Matsushima and Morell, 2001). 
Using the cuprizone model, the BBB stays intact (Bakker and Ludwin, 1987) 
and de-remyelination can be analyzed without infiltration of T cells and periph-
eral macrophages. The extent of de- and remyelination is strongly influenced by 
mouse age, gender, strain and the dose of cuprizone used (Matsushima and 
Morell, 2001; Ludwin, 1980; Armstrong et al., 2002; Blakemore, 1972). The cu-
prizone model has already been used for decades (Ludwin, 1978; Gudi 2010).  
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 Available treatments for MS 
 
Up to date, there is no cure for MS. Treatments focuses on accelerating the re-
covery from attacks, slowing the progression of the disease and managing the 
symptoms. For example, corticosteroids are being used for acute intervention, it 
has been shown to increase the speed of recovery after relapses. Corticoster-
oids have potent anti-inflammatory and immunosuppressive properties. Beta 
interferons-1a and -1b, are the most commonly used medication for MS. Inter-
feron beta achieves an equilibrium of pro- and anti-inflammatory agents in the 
brain, decreasing the number of inflammatory cells crossing the BBB. Interferon 
beta therapy leads to a reduction of neuroinflammation. 
Treatments that inhibit immune cell trafficking include Natalizumab and Fin-
golimod, both treatments work by inhibiting the entry of T cells to the CNS. An-
other approach is being applied to promote immune cell depletion.  
Treatments for this approach include Alemtuzumab and Rituximab. 
Alemtuzumab (Lemtrada), decreases relapses by targeting a protein on the sur-
face of immune cells casuing a depletion in T cells. This can decrease the dam-
aged caused to nerve cells by the attacking immune cells. Several treatments 
were investigated in an effort to influence immune cells including dimethyl 
fumarate and Laquinimod. Dimethyl fumarate was reported achieving a signifi-
cant positive result concerning relapse rate and progression in phase III clinical 
trial. And it was recommended for approval in the European Union in 2013 as 
an MS therapy. Both treatments have shown reduced relapses in patients with 
MS. 
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Other treatments are also used that works on inhibiting immune cell replication 
such as Mitoxantrone and Teriflunomide. Mitoxantrone (Novantrone), an im-
munomodulatory drug. Which is suggested that effects and works as an im-
munomodulatory substance, still the mechanism behind is not fully reported. 
Teriflunomide (Aubagio) stops and inhibits immune cells mitosis (including T- 
and B-cells) that attack and damage the CNS. 
Different treatments are also available for MS signs and symptoms including, 
physical therapy, muscle relaxants and medications to reduce fatigue. Also dif-
ferent medications could be adviced for depression, pain, sexual dysfunction, 
bladder or bowel control problems that are associated with MS (Mayo Founda-
tion for Medical Education and Research, 2014). 
 T cells and glia in MS  
 
T cells play an important role in MS, thus considered by many an immune me-
diated disease. Therefore, T cells have been a major research focus. CD8+ T 
cells can be observed within MS lesions at all disease stages, significantly out-
numbering CD4+ cells. CD8+ cells work as cytotoxic cells, activated in the pe-
riphery and invading the brain or spinal cord. Memory CD8+ cells are found in 
high numbers in blood and CSF of MS patients (Correale et al., 2010). CD8+ T 
cells are associated with axonal injury in early MS (Barnett et al., 2009). CD4+ 
Th1-like cells encourage pro-inflammatory cytokines and stimulate cellular im-
munity, while CD4+ Th2-like cells aid cytokines and encontribute to humoral 
immunity. CD4+ T cells, naïve or activated, were reported to have abnormalities 
in number and/or function in MS patients vs. controls (Peterson et al., 2014).  
The most widely used animal model to study T cells in MS is the experimental 
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autoimmune encephalomyelitis (EAE) model, but still these models do not mim-
ic all aspects of the disease. 
In neuroinflammation or demyelination astrocytes are stimulated and astro-
gliosis can be observed leading to the release of free radical nitric oxide (NO), 
known to be toxic to neurons and oligodendrocytes and may induce neuro-
degeneration (Brown, 2007).  
 
Figure 2: Astrocytes orchestrate CNS inflammation (Peterson et al., 2014). 
 
In chronic cases like neurodegenerative diseases, astrocytes could play a role 
in pathophysiology, demonstrated in figure 2 (Bush et al., 1999). In demye-
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lination, it was reported that astrocytes recruit microglia to engulf myelin debris 
helping to promote remyelination. Hence, astrocytes play a dual role beneficial 
and damaging in the same time. 
Microglia are the resident immune cells of the CNS. They play different roles 
from acting as antigen presenting cells (APCs), producing cytokines, to their 
involvement in phagocytosis. Activated microglia are documented in all MS pa-
tients and specially in progressive subtypes.  
They produce cytotoxic and pro-inflammatory cytokines, reactive oxygen and 
nitrogen intermediates (Merson et al., 2010). Microglia are likely to be an im-
portant player in the MS damage process, and are particularly involved in axon-
al injury (Howell et al., 2010). On the other hand, microglia may play a promot-
ing role by secreting brain derived neurotrofic factor (BDNF), neurotrophin-3 
(NT3), insulin growth factor (IGF-1) (Gandhi et al., 2010).  
Microglia activation is a complex two-way process represented by a gradual 
transformation of resting microglia into different activated phenotypes (Ketten-
mann et al., 2011).  
As a result of this complex and multistage process it is almost impossible to de-
fine a distinct microglial status based on morphology or surface markers, shown 
in figure 4. The so-called activated microglia M1 (neurotoxic phenotype) and 
M2a-c (neuroprotective phenotypes), seems to be an oversimplification (Ran-
sohoff et al., 2009; Chhor et al., 2013; Peterson et al., 2014). 
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Figure 3: Microglial activation as a continuous multistage process (Kettenmann et al., 
2011).  
 
Oligodendrocytes loss and axonal damage leading to demyelination and astro-
cytic scars formation can be observed in variable degrees in MS throughout the 
CNS. They die by apoptosis before the formation of demyelinating plaques (Ar-
temiadis et al., 2010). As reported, activated astrocytes and microglia secrete 
different cytotoxic cytokines and free radical species under stress and inflam-
mation. Oligodendrocytes are sensitive to oxidative stress because of the high 
metabolic rate to synthesize myelin. Thus, it was proposed that intrinsic apopto-
sis caused by oxidative stress is a major cause for oligodendrocyte loss in MS. 
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Thus how these cells act in de- and remyelination and orchestrate together is a 
major path to understand MS better.  
 
• Cell based 
- CD4+ T cells sensitized to myelin antigens 
- Antigen-specific cytotoxic CD8+ T cells 
- Astrocyte disturbance 
• Immune system factors 
- Proinflammatory cytokines 
- Demyelinating antibodies 
- Complement cascade components 
- Bystander demyelination following infectious super antigen cell activation 
• Hypoxic/ischemic stress 
- Reactive oxygen or nitrogen species 
• CNS tissue infection 
• Axonal dysregulation with secondary myelin loss 
• Excitatory amino acids 
- Glutamate 
• Proteolytic, lipolytic enzymes 
• Fas antigen–ligand interactions 
Table 1:  Possible basis for myelin and oligodendrocyte injury in MS (Syed and Rizvi,  
2011). 
 
During demyelination, astrocytes recruit microglia to engulf myelin debris; at this 
time oligodendrocyte precursor cells (OPCs) of adult CNS stem/precursor cells 
differentiate to mature oligodendrocytes to start remyelination. OPCs are the 
main source of remyelination; without these cells recovery and remyelination 
would be impossible. But remyelination in MS is ultimately limited and often 
fails. As suggested, one of the main reasons of this failure is that the reactive 
astrocytes partially suppress the adequate proliferation and differentiation of 
OPCs to form mature myelin-producing oligodendrocytes. The exact basis for 
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oligodendrocyte and myelin loss is still up to date not fully understood (Mi et al., 
2009). 
Demyelination is not always permanent in MS, thus spontaneous remyelination 
occurs after demyelination, but in most cases it is not complete especially in the 
chronic phases of the diseases where the OPCs reservoir is overwhelmed 
(Lucchinetti et al., 1999). FTY720, a sphingosine-1-phosphate receptor modula-
tor used in the treatment of relapsing MS subtypes, was reported to enhance 
myelin repair in a kindling mouse model. Therefore, sphingolipids could be a 
major research focus in helping to achieve faster and complete remyelination 
(Gol et al., 2017).  
 Sphingolipids  and Acid Sphingomyelinase  
 
Sphingolipids are structural and functional components of all biological mem-
branes, consisting of over 100 bioactive lipids, involved in many cellular func-
tions (Ogretmen and Hannun 2004; Ponnusamy et al., 2010; Chen et al., 2012; 
Podbielska et al., 2012).  
Sphingolipids share a sphingosine (2-amino-4-octadecene-1, 3-diol) backbone 
linked via an amide bond to a fatty acid (forming ceramide), or being phosphory-
lated forming sphingosine- 1-phosphate. Ceramide can be modified to form gly-
cosphingolipids, sphingomyelin, or ceramide-1-phosphate, see figure 5. The 
metabolism of sphingolipids is highly sophisticated and carefully regulated (Mul-
len et al., 2012). In the recent years, sphingolipids were increasingly linked and 
reported to play important roles in the pathophysiology of several neuroinflam-
matory diseases, especially MS, but also others such as stroke, dementia and 
inflammatory neuropathies (Gulbinn et al., 2013). 
Sphingolipids in MS 
 
21 
 
The exact function of sphingolipids in neuroinflammation is not fully understood, 
it includes different mechanisms; apoptosis, astrogliosis, leukocyte activation, 
leukocyte trafficking and receptor clustering (Jana and Pahan, 2010; Gulbins et 
al., 2013, Maceyka et al., 2014). Nervous system cell subtypes have a vast rep-
ertoire of sphingolipids. S1P receptors are widely expressed in brain cells (Yu et 
al., 2012; Choi and Chun 2013). 
 
 
Figure 5: The sphingolipid signaling pathway (Brunkhorst et al., 2014). 
 
Studies reported the inhibition of sphingosine kinase or S1P receptor decreases 
astroglial proliferation as well as gliosis (Wu et al., 2008). As mentioned earlier, 
FTY720 - the S1P agonist - was applied to TNFα-treated human astrocytes, and 
showed a reduction in the release of monocyte chemotactic protein-1, docu-
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menting decreased pro-inflammatory reaction of astrocytes (Van Doorn et al., 
2010).  
Sphingomyelinases are a family of enzymes that catalyze the breakdown of 
sphingomyelin into ceramide. Discovered in 1940 by Thannhauser and Reichel 
(Thannhauser, 1940), Acid sphingomyelinase (ASM) was first clearly described 
by Gatt (Gatt, 1963). The gene responsible for ASM is SMPD1, found on chro-
mosome 11p15.4; encoding a 629 amino acid polypeptide (Schuchman et al., 
1992). It has a lysosomal form (75 kDa) and a secreted form (57 kDa) (Ferlinz 
et al., 1994).  
ASM converts sphingomyelin to ceramide releasing it in the outer layer of the 
cell membrane causing the formation of ceramide-rich microdomains fusing to-
gether. And forming rafts which re-organize cell signaling proteins, cluster re-
ceptor molecules and amplify signals (Bianco et al., 2009; Gulbins and Li, 2006; 
2013). Also, the stimulation of T or B cells (via the co-stimulatory receptors, 
CD28 and CD40, respectively) led to the activation of acid sphingomyelinase 
(ASM) and release of ceramide (Stoffel et al., 1998; Gulbins et al., 2013).  
ASM was shown to be activated by the inflammatory cytokines TNFα and IL-1, 
as well as by oxidative stress. As mentioned, ASM was reported to be upregu-
lated in reactive astrocytes in MS lesions. Adding to this, ASM-derived ceramide 
decreases the barrier function of brain endotheilal cells at the BBB (Kim Hye et 
al., 2011; Kim SunJa et al., 2012; Lopes. et al., 2016). 
 Sphingolipids in MS and de/remyelination 
 
Research concerning sphingolipids and its implication in MS has been signifi-
cantly increased in the past years. But still more research is needed to under-
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stand this complex interaction. Studies showed the presence of anti-
sphingomyelin antibodies in the cerebrospinal fluid (CSF) of MS patients, in ad-
dition to that it was reported its role in apoptosis, T cell trafficking, astrocyte ac-
tivation and receptor clustering (Kanter et al., 2006; Jana and Pahan, 2007; Wu 
et al., 2008; Yuan et al., 2012; Gulbins et al., 2013). 
De- and remyelination are major research focus in MS. Thus, the sphingosine-
1-phosphate analogue Fingolimod, a broadly used MS treatment, has been 
shown to enhance cell survival of human oligodendrocytes in vivo (Miron et al., 
2008; Brunkhorst et al., 2014) and to reduce demyelination in cuprizone-treated 
mice by indirect effects on glial cells (Kim et al., 2011; Gol et al., 2017). 
ASM hydrolyses sphingomyelin to ceramide which was linked to apoptotic sig-
naling and the formation of ceramide-enriched platforms. Ceramide was also 
described to be increased in CSF of MS patients (Vidaurre et al., 2014).  And 
exposure of rat neurons to ceramide containing CSF can lead to neuronal mito-
chondrial and axonal damage (Vidaurre et al., 2014). Again, astrocytes seem to 
play a detrimental role as they have been described as main cellular source for 
ceramide production in human MS brains with high levels of ASM mRNA (van 
Doorn et al., 2010). As potential therapeutic approach, ASM function can be 
inhibited by well-known drugs, such as tetracyclic anti-depressants, e.g. amitrip-
tyline (Kim Hye et al., 2011; Kim SunJa et al., 2012; Kornhuber et al., 2010). 
Studies documented that inhibitors of ASM such as fluoxetine attenuate the de-
velopment of EAE in mice decreasing neuroinflammation (Yuan et al., 2012; 
Verderio et al., .2012). Similar phenotype was observed in Smpd1-/- rats that 
develop a milder clinical course of EAE together with decreased immune cell 
infiltration to the spinal cord (Yuan et al., 2012). These reports suggest that 
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there is a direct effect and a major role of Acid sphingomyelinase on T cell 
transmigration in EAE (Yuan et al., 2012; Verderio et al., .2012). In addition, 
recent evidence by Lopes et al.,2016 show the involvement of ASM and 
ceramide in the process of T cell migration via ICAM-1 (Intercellular Adhesion 
Molecule-1)  function. It was reported that activated ASM and the formation of 
ceramide lipid rafts provide the proper conditions for ICAM-1 clustering. 
In demyelination and neuroinflammation in general astogliosis and microgliosis 
occur (Gudi et al., 2014). Also, ASM was reported to be upregulated in reactive 
astrocytes in MS lesions (Kim Hye et al., 2011). Also using FTY720, a S1P ag-
onist, in the toxic demyelination model resulted in a decreased demyelination  
compared to untreated animals and increased oligodendrocyte survival in vivo 
(Kim Hye et al., 2011; Gol et al., 2017). Therefore, sphingolipids play an im-
portant part in the demyelination pathway. Hence, the inhibition of ASM by ami-
triptyline, an FDA approved selective serotonind release inhibitor (SSRIs), could 
have direct or indirect effect on de-or remyelination is to be evaluated. 
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2 Aim of work  
 
We chose to study the acid sphingomyelinase/ceramide system in multiple scle-
rosis animal models, as it was reported earlier to play a role in apoptosis, recep-
tor clustering and neuroinflammation.  The ability to inhibit acid sphingomyelin-
ase activity with available ready-to-use pharmacologic agents, such as amitrip-
tyline, that have minimal side effects and have been in clinical use is a great 
advantage.  
The aim of this work was to study and identify the role of acid sphingomyelinase 
in MS pathophysiology in two different MS animal models. The chronic experi-
mental autoimmune encephalomyelitis model giving the opportunity to observe 
the infiltration of T cells to the CNS with the break-down of the blood-brain bar-
rier. The cuprizone model, a toxic demyelination model, where the blood brain 
barrier remains intact, allows the study of de- and remyelination without the in-
terference of the adaptive immune system.  
We hypothesized that the inhibition of acid sphingomyelinase, either by genetic 
knockout or by pharmacological inhibition attenuates the outcome of chronic 
EAE. As a second approach, if our hypothesis proved correct, then acid sphin-
gomyelinase deficiency affects T cell infiltration to the CNS in the chronic EAE 
model.  
Using the cuprizone model we hypothesized that the inhibition of ASM either by 
genetic knockout or by pharmacological inhibition plays a role in de- and/or re-
myelination in the toxic demyelination model. And a positive outcome would be 
observed concerning the effect of ASM deficiency on axonal damage, astro-
gliosis, microgliosis and oligodendrocyte proliferation in experimental de- and 
remyelination. 
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3 Materials and methods 
 Materials 
 Instruments 
Instruments Company 
7500 Fast Real-Time PCR System Applied Biosystems (Darmstadt, Germany) 
Accu jet Pipettes Control BrandTech Scientific (Essex, CT, USA) 
Autoclave 3870 ELV Systec (Wettenberg, Germany) 
Autoclave V-150 Systec (Wettenberg, Germany) 
Axiovert 25 invetiertes Microscope Carl Zeiss Microscopy (Jena, Germany) 
Axiovert 40 CFL Microscope Carl Zeiss Microscopy (Jena, Germany) 
Biofuge 13 Centrifuge Heraeus (Hanau, Germany) 
Biowizard KR-200 Bench Kojair Tech Oy (Vilppula, Finland) 
Eclipse TS100 Invetiertes Microscop Nikon Instruments (Melville, NY, USA) 
Eclipse E600 Fluorescence Microscopy Nikon Instruments (Melville, NY, USA) 
Epson perfection V700 photo scanner  Epson (Munich, Germany) 
Freezer Premium no frost Liebherr (Lindau, Germany) 
Freezer UF75-110 T Colora (Frankfurt, Germany) 
Forced-air laboratory freezer  Liebherr (Ochsenhausen, Germany)  
Forced-air laboratory refrigerator  Liebherr (Ochsenhausen, Germany) 
General Rotator STR4 Stuart Scientific (Staffordshire, UK) 
Ice Machine Eurfrigor Ice Makers Srl (Lainate, Italy) 
InoLab pH 720 pH-meter WTW (Weilheim, Germany) 
Laboratory balance ALS120-4, EW4200, EW420  Kern & Sohn (Balingen, Germany)  
Laboratory centrifuge SIGMA 4K15C  Sigma Laborzentrifugen GmbH (Osterode 
am Harz, Germany) 
Leica SM 2000 R Sliding Microtome  Leica Microsystems Nussloch GmbH 
(Nussloch,Germany)  
Leica TP1020 Tissue Processor  Leica Microsystems Nussloch GmbH 
(Nussloch,Germany)  
Leica EG1150C Cold plate  Leica Microsystems Nussloch GmbH 
(Nussloch,Germany)  
Leica EG1150 H Heated Paraffin Embedding 
Module  
Leica Microsystems Nussloch GmbH 
(Nussloch,Germany)  
Liquid Nitrogen Container KGW-Isotherm (Karlsruhe, Germany) 
Micro-plate reader  TECAN, Sunrise Remote (Männedorf, 
Switzerland) 
Microscope Zeiss Axio Scope  Carl Zeiss (Göttingen, Germany)  
MLA-130 Rotor, Fixed Angle, Titanium for Ultra-
centrifuge  
Beckman Coulter (Brea, USA)  
 
Multiband UV table  Peqlab (Karlsruhe, Germany)  
Multipette® plus  Eppendorf (Hamburg, Germany) 
Nanodrop ND-1000 Spectrophotometer PEQLAB Biotechlonogie (Erlangen, Ger-
many) 
Pipette PIPETMAN Gilson (Middleton, WI, USA) 
Pipette Single-Channel Eppendorf (Hamburg, Germany) 
Pipette Pipetus Hirschmann (Eberstadt, Germany) 
Precision Balance scale 770 Kern & Sohn (Balingen, Germany) 
Precision Balance scale CP 42023 Sartorius (Göttingen, Germany) 
PTC 200 DNA Engine Thermal Cycler MJ Research (St. Bruno, Canada) 
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PURELAB Ultra Water Purification 
system 
Elga (Celle, Germany) 
Refrigerator KG39VVI30 Siemens (München, Germany) 
Rocky 3D Labortechnik Frübel (Lindau, Germany) 
Savant SpeedVac DNA 110 Thermo Scientific (Langenselbold, Germa-
ny) 
Shakers SM-30 Edmund Bühler (Hechingen, Germany) 
Tabletop Centrifuge 4K10 Sigma Laborzentrifugen (Osterode am 
Harz, Germany) 
Tabletop Centrifuge 4K15C Sigma Laborzentrifugen (Osterode am 
Harz, Germany) 
Thermoblock TDB-120 BioSan (Riga, Latvia) 
Thermomixer comfort Eppendorf (Hamburg, Germany) 
Vortex Genie 2 Scientific Industries (Bohemia, NY, USA) 
Vortex Shaker REAX 2000 Heidolph (Schwabach, Germany) 
Water bath Köttermann (Hänigsen, Germany) 
 
 Experimental material 
Experimental materials Company 
Beakers VWR (Darmstadt, Germany) 
Biosphere Filter Tips (10 μl, 200 μl, 1000 μl) Sarstedt (Nümbrecht, Germany) 
BD Plastipak syringe, 1ml  Becton, Dickinson and Company (Heidel-
berg, Germany)  
Bottle Top Filter 500ml, 0.22mm  Sarstedt  (Nürnbrecht, Germany)  
Centrifugentubes (15 ml, 50 ml) Sarstedt (Nümbrecht, Germany) 
Combitips Plus (5 ml, 10 ml) Eppendorf (Hamburg, Germany) 
CryoPure tubes 1.8 ml Sarstedt (Nümbrecht, Germany) 
Cuvettes Sarstedt (Nümbrecht, Germany) 
Dako pen Dako (Glostrup, Denmark) 
Erlenmeyer Flasks Schott (Mainz, Germany) 
Falcon Round bottom test tubes 5 ml BD Biosciences (Heidelberg, Germany) 
Glass Bottles Fisher Scientific (Schwerte, Germany) 
Gloves, Nitril VWR (Darmstadt, Germany) 
Hemocytometer Brand (Wertheim, Germany) 
Homogenizer  Hartenstein, (Würzburg, Germany) 
Isoflurane  Baxter  (Unterschleißheim, Germany) 
Laboratory glassware  Schott (Mainz, Germany) 
Luerlock syringe 1 ml  BD Biosciences (Durham, USA)  
Microscope slides 76 ´ 26 mm  Gerhard Menzel (Braunschweig, Germa-
ny)  
15 ml, 50 ml, round bottom 50 ml conical centri-
fuge tubes  
Sarstedt (Nürnbrecht, Germany)  
 
Parafilm M all-purpose laboratory film  Pechiney Plastic Packaging (Chicago, 
USA) 
pH-indicator Strips pH 0 - 14 universal indicator  Merck (Darmstadt, Germany) 
Pipette tip 10 μl, 200 μl, 1000 μl  Sarstedt (Nürnbrecht, Germany) 
Syringe filter 0.22 μm  Carl Roth (Karlsruhe, Germany) 
Syringe, 2ml, 5ml, 10ml, 20ml  B Braun (Tuttlingen, Germany)  
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 Chemicals 
Chemicals Company 
(3-Aminopropyl) triethoxysilane Sigma Aldrich (Taufkirchen, Germany) 
2-methyl butane  Sigma Aldrich (Taufkirchen, Germany) 
2-Propanol  Carl Roth (Karlsruhe, Germany) 
Agarose Biozym (Oldendorf, Germany) 
Acetone Hedinger (Stuttgart, Germany) 
Amino-ethylcarbazol (AEC)  Sigma-Aldrich Chemie (Steinheim, 
Germany) 
Amitriptyline  Sigma (Schnelldorf, Germany) 
Ammonium chloride  Sigma-Aldrich Chemie (Steinheim, 
Germany)  
Antibiotic-antimycotic  Invitrogen (Darmstadt, Germany)  
Aquatex Merck (Darmstadt, Germany) 
Bovine Serum Albumin (BSA) Sigma Aldrich (Taufkirchen, Germany) 
Casein Fluka (Buchs, Switzerland) 
Citrate acid Serva (Heidelberg, Germany) 
Cuprizone Sigma Aldrich (Taufkirchen, Germany) 
Dimethyl sulfoxide (DMSO)  Sigma Aldrich (Taufkirchen, Germany) 
Diaminobenzidin-Hydrochlorid (DAB) Sigma Aldrich (Taufkirchen, Germany) 
DNA Ladder (100 bp, 1 kb) New England Biolabs (Frankfurt am Main, 
Germany) 
dNTP Mix Roche (Mannheim, Germany) 
Dithiothreitol (DTT) Sigma Aldrich (Taufkirchen, Germany) 
Entellan®mouting media VWR (Darmstadt, Germany) 
Ethidiumbromid Carl Roth (Karlsruhe, Germany) 
Ethanol Sigma Aldrich (Taufkirchen, Germany) 
Glycerol Sigma Aldrich (Taufkirchen, Germany) 
H2O2 Otto Fishar (Saarbrueken, Germany) 
HCl Sigma Aldrich (Taufkirchen, Germany) 
Hexamer Random Primer Invitrogen (Darmstadt, Germany) 
Isoflurane Baxter (Unterschleißheim, Germany) 
Incomplete Freund Adjuvant  DIFCO Laboratories (Michigan,USA)  
Isopropanol  Carl Roth (Karlsruhe, Germany) 
Lithium Carbonate Sigma Aldrich (Taufkirchen, Germany) 
Luxol Fast Blue (LFB) RAL diagnostics (Martillac,France) 
KHCO3 Merck (Darmstadt, Germany) 
KCl Merck (Darmstadt, Germany) 
MgCl2 Fluka (Buchs, Switzerland) 
Mayers Hematoxylin  VWR (Darmstadt, Germany) 
Methanol Sigma Aldrich (Taufkirchen, Germany) 
Mycobacterium tuberculosis H37 Ra  BD Biosciences (Durham, USA)  
Myelin Oligodendrocytic peptide 35-55  Charite (Berlin, Germany)  
Paraformaldehyd (PFA) Merck (Darmstadt, Germany) 
Pertussis toxin  Enzo life Sciences (Lörrach, Germany)  
Periodic Acid  Merck (Darmstadt, Germany) 
Schiff’s reagent Merck (Darmstadt, Germany) 
Sodium acetate  Merck (Darmstadt, Germany) 
Sucrose VWR (Darmstadt, Germany) 
Sphingolipids in MS 
 
29 
 
Sodium carbonate  Sigma-Aldrich Chemie (Steinheim, 
Germany)  
Triton X-100 Sigma Aldrich (Taufkirchen, Germany) 
TRizol Sigma Aldrich (Taufkirchen, Germany) 
Tween 20 Sigma Aldrich (Taufkirchen, Germany) 
Tissue Tek  Sakura Finetech Europe (Amster-
dam,Netherlands)  
Trypan Blue  Sigma-Aldrich Chemie, Steinheim, 
Germany)  
Xylene Otto Fischar (Saarbrücken, Germany) 
 
 Kits  
Kit Company 
Vectastain Elite ABC kit Rat IgG Vectastain (Wertheim-Bettingen, 
Germany) 
DyNAmoTM Flash SYBR Green qPCR Kit Roche Applied Sciences  (Mannheim, 
Germany) 
SuperScript® III Reverse Transcriptase Invitrogen (Darmstadt, Germany) 
 
 Oligonucleotides  
Gene Primer forward 5' - 3' Primer reverse 5' - 3' 
mouse GAPDH  ACAACTTTGGCATTGTGGAA GATGCACGGATGATGTTCTG 
mouse Il-1β                GAAGAAGAGCCCATCCTCTG TCATCTCGGAGCCTGTAGTG 
mouse FGF1 TTTATACGGCTCGCAGACAC GCTTACAGCTCCCGTTCTTC 
mouse Mrc1 TGATTACGAGCAGTGGAAGC GTTCACCGTAAGCCCAATTT 
mouse FGF2 CCAACCGGTACCTTGCTATG TATGGCCTTCTGTCCAGGTC 
 
 Antibodies 
Antibody Company 
mouse monoclonal anti Iba-1 Clone, 20A12.1 Millipore (Schwalbach, Germany) 
rabbit polyclonal anti Iba-1 Wako (Neuss, Germany) 
rabbit polyclonal anti CD3 (ab5690) Abcam (Cambridge, UK) 
mouse monoclonal  anti Synaptophysin (ab8049) Abcam (Cambridge, UK) 
rabbit polyclonal anti Olig-2 ab81093 Abcam (Cambridge, UK) 
rabbit polyclonal anti MBP (ab40390) Abcam (Cambridge, UK) 
Biotin SP conjugated goat anti mouse (ab128976) Abcam (Cambridge, UK) 
rabbit polyclonal anti APP (a8717) Sigma-Aldrich (St. Louis, USA) 
rat monoclonal anti GFAP (13-0300) Invitrogen (Darmstadt, Germany) 
goat anti rabbit Alexa 488 Conjugate (1670152) Invitrogen (Rockford,USA) 
Biotin SP conjugated Affinipure goat anti rabbit 
IgG(H+L) 
Jackson Immunoresearch Laboratories 
(Baltimore,USA) 
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 Buffers and media 
Recipe  Chemicals Amount Concentration 
10X Citric buffer Citric acid  2.014g  
Up to1 Liter 
10mM 
10x PBS NaCl  
KCl  
Na2HPO4  
NaH2PO4 x H2O 
dest. H2O  
Adjust to pH 7.4 
400g 
10g 
71g 
69g 
Up to 5 liters 
1.37 M 
27 mM 
100 mM 
100 mM 
10x TBS Tris   
NaCl  
dest. H2O 
Adjust to pH 7.4 
302.5 g 
425 g 
Up to 5 Liter 
 
500 mM 
1.45 M 
5x TBE Tris  
Borat  
0.5 M EDTA [pH 8.0] dest. 
H2O  
270 g  
137.5 g  
100 ml  
Up to 5 Liter 
446 mM 
446 mM 
10 mM 
 
Blocking buffer PBS 
Casein 
Tween 20 
Triton X 
 As needed 
0.02% 
0.1 % 
0.01% 
4% PFA dest. H2O  
NaOH 
PFA 
10X PBS 
 
Up to 1 liter 
100µl 
40g 
100 µl 
 
10N 
 
 Methods 
 Mice 
 
Acid sphingomyelinase genetically deficient mice (Smpd1-/-; protein: ASM, gene 
symbol: Smpd1) and wild type (C57BL/6J) littermates were obtained from our 
breeding facility (Forschungs- und Verfügungsgebäude der Medizinischen 
Fakultät des Universität des Saarlandes, 61.4). All mice were maintained in a 
pathogen-free environment. Food and water were available ad libitum.  The 
genotype of the Smpd1-/- mice was confirmed by polymerase chain reaction 
(PCR) prior to experimentation. All animal experiments were approved by the 
regional council in Saarland, Germany.  
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Experiments were ended when animals lost more than 15% of weight. To that 
concern twelwe animals dropped out from the chEAE experiments. Paralyzed 
animals were given HydroGel and food pellets placed at the base of the cages.  
All animal experiments were performed in the experimental surgery laboratory 
(Medizinischen Fakultät des Universität des Saarlandes, 65) and 
neuroimmunology laboratory (Medizinischen Fakultät des Universität des 
Saarlandes, 90). 
 Immunization, clinical scoring guide and treatment protocols  
 MOG emulsion preparation  
 
The emulsion used for immunization was prepared by combining MOGaa35-55 
with 10 mg/ml CFA in a 1:1 ratio in a latex-free syringe, for an end concentration 
of 300 µg MOG/200 µl. The solution was mixed manually with a pipette for 1 
min and put on ice. The solution was then homogenized using a probe sonicator 
for 60 sec (2 cycles, 45% power) and again put on ice for 1 min.  
The sonication was repeated as previous and then the reagent frozen at -20ᵒC 
for 24 h. After 24 h, the emulsion was thawed and the 2 cycles of sonication (as 
described above) were repeated. The emulsion was either injected immediately 
or stored at -20ᵒC for up to one week. 
 Immunization  
 
Induction of chronic EAE (chEAE) in 6-8 weeks old (Smpd1-/- and wildtype) fe-
male mice was achieved by injecting 200 µl of the MOG emulsion, as prepared 
above, subcutaneously into the axillary and inguinal lymph node regions (50 
µl/lymph node region) at day 0 and day 7. On days 0 and 2, 300 ng pertussis 
toxin dissolved in PBS up to a volume of 200 µl was injected intra-peritoneally 
(i.p.). 
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 Clinical scoring guide  
 
Clinical disease was checked daily and scored as previously described (Engel-
hardt et al., 1997):  
- 0.5: Limp tail 
- 1: Hind leg weakness  
- 2: Hind leg paraparesis.  
- 3: Hind leg paraplegia and incontinence  
- 4: Fore limb and hind leg paresis.  
- 5: Death  
 
 Amitriptyline treatment protocol  
At the start of weight loss between days 12 and 16 post-immunization (Fig.I) 
and continuing for 8 days, 25 mg/kg amitriptyline dissolved in sterile distilled 
water was injected i.p. every 12 h in WT chEAE mice. The bi-daily (b.i.d.) dos-
ing schedule was chosen to maintain a constant plasma level of amitriptyline 
(Teichgraber et al., 2008). Sterile PBS was injected as control.  
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Figure 4: Weight measurments of Smpd1 genetically deficient mice and wild-type litter-
mates during chEAE.  
 
 Induction of experimental de- and remyelination, treatment groups 
and amitriptyline treatment 
 Cuprizone diet  
 
Induction of demyelination was achieved by feeding 8 weeks old (Smpd1-/- and 
wildtype) male littermate mice with 0.2% cuprizone mixed freshly everyday into 
grounded standard rodent chow. The cuprizone diet was maintained for 5 
weeks (acute demyelination) or 12 weeks (chronic demyelination) see below; 
different experimental groups. To study remyelination, the cuprizone diet was 
replaced with normal diet for 1 or 2 weeks to allow recovery.  
 Different experimental groups  
 
 5 weeks acute demyelination (n=mice number) 
• C57BL/6J  + normal chow (control) (n=5) 
• Smpd1-/-    + normal chow (control) (n=5) 
• C57BL/6J  + cuprizone  (n=5) 
• Smpd1-/-    +  cuprizone (n=5) 
• C57BL/6J  +  normal chow with 1 week Amitryptiline treatment (baseline) (n=5) 
• C57BL/6J   +  cuprizone  with 1 week   PBS injections (control) (n=5) 
• C57BL/6J   +  cuprizone  with  1 week  Amitryptiline treatment (n=5) 
• C57BL/6J   +  cuprizone with 2 weeks Amitryptiline treatment (n=5) 
Remyelination after 5 weeks demyelination   
• C57BL/6J   + cuprizone and 1 week recovery (n=5) 
• Smpd1-/-     + cuprizone and 1 week recovery (n=5) 
• C57BL/6J   + cuprizone and 1 week recovery +  Amitriptyline treatment (n=5) 
• C57BL/6J   + cuprizone and 2 weeks recovery  (n=5) 
• C57BL/6J   + cuprizone and 2 weeks recovery + Amitriptyline treatment (n=5) 
• C57BL/6J   + cuprizone and 2 weeks recovery + PBS (n=5) 
• Smpd1-/-     + cuprizone and 2 weeks recovery (n=5) 
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12 weeks chronic demyelination  
• C57BL/6J   + 12 weeks cuprizone (n=5) 
• Smpd1-/-     + 12 weeks cuprizone (n=5) 
Remyelination after 12 weeks demyelination  
• C57BL/6J   + 12 weeks cuprizone and 2 weeks recovery (n=5) 
• Smpd1-/-     + 12 weeks cuprizone and 2 weeks recovery (n=5) 
 
 Amitriptyline treatment protocol  
 
For all of the amitriptyline treated groups, 25 mg/kg amitriptyline dissolved in 
sterile distilled water was injected i.p. every 12 h, as mentioned previously, for a 
treatment period of 2 weeks. Sterile PBS was used as control. 
 Tissue collection 
 
For the chEAE groups, mice were scarified at day 45 p.i. and perfused via the 
left cardiac ventricle with ice-cold PBS followed by 4% PFA in phosphate buffer. 
Brains and spinal cords were harvested, and either dehydrated for paraffin em-
bedding or placed in Tissue-Tek and snap-frozen in isopentane with liquid nitro-
gen at -80ᵒC for cryo-sectioning. The frozen tissue was cut in 25µm or 10 µm 
sections on a cryostat and fixed with acetone at -20ᵒC. Paraffin embedded spi-
nal cords were also sectioned in 25µm sections on a microtome. Both frozen 
and paraffin-embedded tissue sections were placed on silanized slides to en-
sure adherence during staining protocols. For the de-remyelination groups, 
mice were anesthetized with isoflurane and perfused via the left cardiac ventri-
cle with PBS for gene expression analysis or with 4% PFA for immunohisto-
chemistry studies. Brains were collected post-fixed in 4% PFA and dehydrated 
for paraffin embedding. Tissues were coronally sectioned each 5μm in thick-
ness on a microtome and dried at 37ᵒC overnight. Sections between bregma -
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0.82mm and bregma -1.82mm according to the mouse atlas by Paxinos and 
Franklin (2001) were analyzed. Before perfusion blood from amitriptyline treated 
animals was collected from the vena cava for later measurements of nortripty-
line (data not shown). 
 Histology  
 Luxol Fast Blue Stain (LFB)     
 
Demyelination in the corpus callosum was examined by staining coronal brain 
sections with Luxal fast Blue, staining myelin in blue and periodic acid-Schiff, 
staining demyelinated axons in pink. Detailed Procedure as follows: 
1. Put LFB solution in 60ᵒC oven. 
2. De-paraffin slides in xylene (1)  for 2 mins 
3. De-paraffin slides in xylene (2)  for 2 mins 
4. Clear slides in 100% alcohol (1) for 2 mins 
5. Clear slides in 100% alcohol (2) for 2 mins  
6. Hydrate slides in 95% alcohol for 2 mins  
7. LFB solution for 2 hours at 60ᵒC  
8. Take out let stand (cool) for 5 mins 
9. Rinse in 95% alcohol to remove excess stain  
10. Rinse in dest H2O for 2 mins 
11. Differentiate in 0.05% lithium carbonate 4-5 dips 
12. Differentiate in 70% alcohol until grey 
13. Wash in H2O for 1 min 
14. 0.5% periodic acid for 5 mins 
15. Schiff’s reagent for 15 mins 
16. Wash in running tap water for 10 mins 
17. Hematoxylin for 20-40 seconds 
18. Wash in running tap water for 2 mins 
19. Dehydrate in 95% alcohol for 30 seconds 
20. Dehydrate in 100% alcohol (3) for 1 min 
21. Dehydrate in 100% alcohol (4) for 2 mins 
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22. Clear in Xylol (3) for 2 mins  
23. Clear in Xylol (4) for 2 mins 
24.  Mount in Entellan 
 
 Immunohistochemistry  
 GFAP, Iba-1, CD3, Olig-2, synaptophysin and APP staining  
 
In order to quantify astrogliosis, microgliosis, oligodendrocyte cell numbers and 
axonal damage for the de- and remyelination groups. 5μm coronal sections 
from the brains of treated animals were cut and mounted on silanized slides and 
stained for primar antibodies. For the chEAE animals 25μm serially sectioned 
spinal cords were used to quantify CD3 positive cell numbers, astrogliosis and 
microgliosis in Smpd1 genetically deficient mice and corresponding WT litterma-
tes. The immunohistochemical staining was performed as follows on paraffin 
sections: 
1. The slides were serially deparaffinized in the solutions (2 x 5 min Xylene, 
2 x 5 min 100% ethanol, 5 min 96% ethanol, 5 min 70% ethanol, and 5 
min 50% ethanol). 
2. Antigen retrieval by cooking the sections in 1× citrate buffer (10 mM, pH 
6.0) in a Microwave oven, 560 watts, 3 min × 5 times. Refill with buffer 
between each cooking. Cool down slowly by leaving on the bench for 
>30 min after cook. 
3. The endogenous peroxidase of the tissue was inactivated via incubating 
the slides in the mixture of H2O2 /Methanol/dH2O buffer, RT, 30min. 
4. Wash slides with TBS, 5 min × 2 times and then with TBS-T, 5 min, 
once. 
5. Block with blocking buffer (0.2% Casein (w/v) + 0.1% Tween 20 + 0.1% 
Triton X- 100 in PBS), RT, 1hr. 
6. 1st Antibody reaction: Concentrations shown below. Diluted in dilution 
buffer (0.02% Casein (w/v) + 0.01% Tween 20 + 0.01% Triton X-100 in 
PBS), 100 µl/section, incubate at 4 °C, overnight. 
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7. Wash as step 4. 
8. 2nd Antibody reaction: biotinylated goat-anti-rabbit or biotinylated goat-
anti-mouse depending on the primary antibody. Concentrations shown 
below. Secondary antibody diluted in dilution buffer (0.02% Casein (w/v) 
+ 0.01% Tween 20 + 0.01% Triton X-100 in PBS). Incubate at RT 1hr. 
9. Meanwhile prepare avidin-biotin-enzyme-complex, ABC kit (Vectastain). 
Dilute reagent A and reagent B in PBS/T (both 1:100), 100 µl/section. In-
cubate in dark, at least 30min before use, allowing the formation of avi-
din-biotin HRP complex. 
10. Wash as step 4. 
11. Incubate with ABC reagent. RT, 1hr. 
12. Wash as step 4. 
13. Develop with DAB, 45 sec, and then wash with dH2O, 3 times 
14. Counterstaining with Hematoxylin, 20 sec, forward to dH2O wash 3 
times. Then develop in running tap water for 5 min, and then change 
back to dH2O. 
15. Dehydration: serially treat the slides in the following solutions: water, 3 
min, 50% ethanol, 3 min 70% ethanol, 3 min 96% ethanol, 2 x 3 min 
100% ethanol, 2 x 5 min Xylene. 
16. Mount the slides with Entellan (Merck), and then cover the tissue with 
cover glass. 
 
Primary Antibody Concentration Company 
Glial fibrillary acidic protein (GFAP) 1:1000 Invitrogen (Darmstadt, Germany) 
Ionized calcium-binding adapter 
molecule 1 (Iba-1) 
1:200 Millipore (Schwalbach, Germany) 
Oligodendrocyte transcription 
factor (OLIG-2) 
1:1500 Abcam (Cambridge, UK) 
Synaptophysin 1:50 Abcam (Cambridge, UK) 
Amyloid precursor protein (APP) 1:1000 Sigma-Aldrich (St. Louis, USA) 
Cluster of differentiation-3 (CD3) 1:100 Abcam (Cambridge, UK) 
Secondary Antibody Concentration Company 
Biotin conjugated Affinipure goat 
anti rabbit IgG(H+L) 
1:200 Jackson Immunoresearch Laborato-
ries (Baltimore,USA) 
Biotin SP conjugated goat anti 
mouse (ab128976) 
1 drop Abcam (Cambridge, UK) 
Table 2: The used primary and secondary antibodies. Respective concentrations are 
summarized. 
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 MBP fluorescence staining 
 
Brain coronal paraffin sections of 5µm thickness from mice of de-remyelination 
studies, stained with primary antibody against MBP to measure the fluores-
cence intensity of myelin in the corpus callosum were stained as follows: 
1. The slides were serially deparaffinized in the solutions (2 x 5 min Xylene, 
2 x 5 min 100% ethanol, 5 min 96% ethanol, 5 min 70% ethanol, and 5 
min 50% ethanol). 
2. Wash in PBS 5 mins. 
3. Antigen retrieval by cooking the sections in 1× citrate buffer (10 mM, pH 
6.0) in a Microwave oven, 560 watts, 3 min × 5 times. Refill with buffer 
between each cooking. Cool down slowly by leaving on the bench for 
>30 min after cook. 
4. Wash in PBS-T, 5mins. 
5. Block for 1hr (5% goat serum in PBS-T). 
6. Primary antibody, rabbit polyclonal anti-MBP at 1:100 diluted in 1% goat 
serum in PBS-T. 
7. Incubate overnight at 4ᵒC. 
8. Wash in PBS-T, 5 mins.    
9. Add secondary antibody, Alexa fluor 488 goat anti rabbit at 1:100 diluted 
in 1 % goat serum in PBS-T, 1hr at RT. 
10. Wash in PBS, 5 mins. 
11. Check for Fluorescence under microscope. 
12. Mount with Mowiol. 
 Quantification of de- and remyelination 
 
The midline corpus callosum as diagrammed below in Fig. 7 was examined 
(Mason et al., 2000). Sections between bregma -0.82 mm and bregma -1.82 
mm according to the mouse atlas by Paxinos and Franklin (2001) were ana-
lyzed. All manual scorings were performed completely blind to the animal’s 
genotype and the treatment group. The LFB stained sections were scored 
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based on the relative ratio of blue or pink fibers detected, on a scale from zero 
to three, three being completely myelinated and zero being completely demye-
linated (Skripuletz et al., 2012). Five animals per group were included. Two to 
three slices (5μm) per animal was stained, taking two pictures per slide to be 
scored. 
 
Figure 5: Representation of the corpus callosum. And the level at which brain tissue sec-
tions were stained and scored in the CC for de- and re- myelination (v = ventricle) (Mason 
et al., 2000). 
 
 Quantification of inflammation and lesions in spinal cords of 
chEAE mice 
 
Longitudinally sectioned 5µm thick paraffin embedded spinal cords from chEAE 
experiments were stained with LFB/PAS.  In the control tissue there is no influx 
of leukocytes or accumulation within the tissue. During chEAE there is evident 
infiltration of leukocytes observed in the pial lining and subsequently in the pa-
renchyma. The number of lesions within a spinal cord section is also indicative 
of the degree of inflammation. Thus, by location and number (˂ or ˃ 5) of le-
sions on each section, a qualitative score can be documented in blinded anal-
yses, with ascending scores representing greater severity. Areas of inflamma-
tion (hypercellularity) are usually correspondent with area of demyelination 
where there is less LFB stain observed. For semiquantitative assessment of the 
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extent of inflammation in the spinal cord, all stained longitudinal sections were 
first evaluated using the scoring system outlined below (DaSilve et al., 2009). 
Two to three different sections per animal were examined blindly without know-
ing the animal’s genotype or the treatment group and the average number of 
lesions per section was documented (DaSilve et al., 2009). 
Table 3: Scoring system used for semi-quantitative assessment of the extent of inflam-
mation. 
Score  Description 
0 Normal 
1 Pial inflammation only, ˂5 lesions/section 
2 Pial inflammation only, ˃5 lesions/section 
3 Beginning of parenchymal inflammation (moving into parenchyma from pia) 
4 Parenchymal inflammation, ˂5 lesions/section 
5 Parenchymal inflammation, ˃5 lesions/section (relatively small parenchymal lesions) 
6 Parenchymal inflammation, ˃5 lesions/section (relatively large parenchymal lesions) 
7 Parenchymal inflammation, with large lesions and holes in tissue  
 
 Quantification of oligodendrocyte and T-cell numbers 
 
Quantification of oligodendrocytes in the cuprizone experiments was achieved 
by manual counting the number of Olig-2 positive cells in the investigated re-
gion. At least two sections per animal. Cell counting was performed using an 
AxioImager Z2 microscope (Zeiss, Germany) and a 20 or 40x objective in the 
medial Corpus Callosum (CCm). For the chEAE tissues 2-3 sections 25µm thick 
slides minimum 100µm apart were counted for CD3-positive cells in an area not 
less than 11x106 µm2 in the thoracic and lumbar regions of the spinal cord. Im-
ages were acquired using an AxioImager Z2 microscope equipped with a Ste-
reo Investigator system (MicroBrightField). Cell numbers were calculated and 
expressed per mm2 for all histological analyses. 
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 Quantification of astrocyte and microglia parameters 
 
For astrocyte and microglia cell count in the cuprizone experiments, 2 to 3 sec-
tions (5µm) per animal were manually counted for GFAP and Iba-1 positive cells 
with clearly visible nucleus at the CCm. As an additional parameter for astro-
gliosis and microgliosis, the surface area covered by GFAP and Iba-1 staining 
was determined using a densitometric scanning procedure (ImageJ, Maryland, 
USA). Results are expressed as relative GFAP or Iba-1 covered area of the 
CCm (percentage of the stained area in relation to the non-stained area) (Zend-
edel et al., 2016). For the chEAE samples, at least 2 longitudinally sectioned 
spinal cord sections 25 µm in thickness with a distance of 150 µm in between 
where counted in an area not less than 11x106 µm2 in the thoracic and lumbar 
regions. All counting was done using an AxioImager Z2 microscope with an ob-
jective of 20x or 40x. Cell numbers are expressed as cells per mm2. All morpho-
logical quantification was performed in a blinded way. 
 MBP fluorescence quantification  
 
Quantification of MBP fluorescence intensity in the CCm of cuprizone treated 
mice was done using the ImageJ software. With the following formula: 
Fluorescence intensity = Integrated Density – (Area of the ROI x Mean fluores-
cence of background readings). 
Measurements were expressed as arbitrary units.  
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 Reverse transcription and quantitative PCR for analysis of gene 
transcripts      
 
Real-time PCR is a quantitative method used to detect the number of PCR tem-
plates such as DNA or complementary DNA in a PCR reaction. Two types of 
real-time PCR are being used: intercalator-based and probe-based. Both proto-
cols need a unique thermocycler set with a sensitive camera that measures the 
fluorescence in every well of the 96-well plate through the reaction. Intercalator-
dependent method known as SYBR green procedure requires a double-
stranded DNA dye in the PCR reaction which will bind to the newly synthesized 
double-stranded DNA, hence giving fluorescence. On the other hand, probe-
dependent real-time PCR known as TaqMan needs a pair of PCR primers and 
an additional flurogenic probe - an oligonucleotide of 20-26 nucleotides with 
both a reporter fluroscentent dye and a quencher dye attached. This probe is 
designed to bind only the DNA sequence between the two specific PCR pri-
mers. Solely a specific PCR product can generate a fluorescent signal in Taq-
Man PCR. In our study, real-time PCR was performed using SYBR green 
(Roche Applied Science) with the 7500 Fast Real-Time PCR System (Life 
Technologies). 
 Corpus callosum RNA isolation with Trizol 
 
Following our laboratory protocol, corpus callosum was isolated from the whole 
brains under a light microscope. Then the total RNA was extracted from the tis-
sue using Trizol (Life Technologies). First strand cDNA was synthesized by 
priming total RNA in addition to hexamer random primers (Life Technologies) 
with a Superscript III reverse transcriptase (Life Technologies). For quantifica-
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tion of gene transcripts, real-time PCR was performed using SYBR green 
(Roche Applied Science) with the 7500 Fast Real-Time PCR System (Life 
Technologies). The quantity of the double-stranded PCR product produced was 
then measured by detecting the FAM dye freed from the SYBR green, which 
attaches to the double-stranded DNA. Threshold cycle (Ct) values for every test 
gene from the replicate PCRs were then normalized to the Ct values for gapdh 
control from the same cDNA prepared. Transcription ratios were calculated as 
2(∆ct)   where ∆Ct is the difference between Ct (gapdh) and Ct (test gene) (Liu Y. 
et al., 2014).  
In detail: 
1. Phase separation: Incubate the homogenized samples for 5 min at room 
temperature to permit complete dissociation of nucleoprotein complexes. 
Then add 0.2 ml of chloroform and shake vigorously by hand for 15 sec, 
and then incubate at room temperature for 3 min. Centrifuge the samples 
at 12,000 x g for 15 min at 4 ᵒC. The sample mixture was separated into 
a lower red, phenol- chloroform phase, an interphase and a colorless up-
per aqueous phase. RNA remains in the aqueous phase. 
2. RNA precipitation: Transfer the colorless aqueous phase to a fresh tube; 
precipitate the RNA from the aqueous phase by mixing with 0.5 ml iso-
propyl alcohol. Incubate at room temperature for 10 min and then centri-
fuge at 12,000 x g for 10 min at 4 ᵒC. The precipitated RNA is the gel-like 
pellet on the bottom side of the tube. 
3. RNA wash: remove the supernatant and wash the RNA once with 1 ml 
75% ethanol. Mix by vortexing and centrifuge at 7,600 x g for 5 min at 4 
ᵒC. 
4. Redissolve the RNA: briefly dry the RNA pellet, incubating for 10 min at 
RT and then dissolve it in appropriate volume of RNase-free water. 
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 Genome DNA degradation prior to RT-PCR 
 
To erase trace genomic DNA contamination in the RNA sample, RQ1 (RNA 
Qualified) RNase-Free DNase (Promega), which is a DNase-I that degrades 
both double-stranded and single-stranded DNA, was used.  
This reaction was set up: 
RNA sample in water 8 µl 
RQ1 RNase-Free DNase 10x Reaction buffer 1 µl 
RQ1 RNase-Free DNase 1 U/ µg RNA 
Nuclease-free water To a final volume of 10 µl 
 
Incubate at 37 ᵒC for 30 min, and then add 1 µl of RQ1-DNase. Stop solution to 
terminate the reaction. The DNase was then inactivated by incubating at 65 ᵒC 
for 10 min. RNA purity and concentration was measured using Nanodrop 2000 
(Thermo scientific). 
 First strand cDNA synthesis 
 
First-strand cDNA was synthesized by priming total RNA with hexamer random 
primers (Invitrogen) and using Superscript II reverse transcriptase (Invitrogen), 
which is an engineered version of Moloney Murine Leukemia Virus RT with re-
duced RNase H activity and increased thermal stability. This enzyme can be 
used to generate cDNA up to 12.3kb.  
Total RNA 3 µg 
Random primer (250 ng/µl) 1 µl 
dNTP mix 10 mM each) 1 µl 
Nuclease-free water To a final volume of 12 µl 
Heat the mixture to 70 ᵒC for 5 min and quick chill on ice for 2min.  
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And then add: 
 
 
The cDNA is ready for use. 
 
 Real-time quantitative PCR 
 
For quantification of transcription level, real-time quantitative PCR with SYBR 
green (Roche Applied Science) using the 7500 Fast Real-Time PCR System 
(Life Technologies).  Reaction setup for SYBR green: 
Faststart universal SYBR green 10 µl 
Forward primer 30 microM 0.5 µl 
Reverse primer 30 microM 0.5 µl 
ddH2O 8 µl 
cDNA 1 µl                                          
 
7500 Fast Real-time PCR setup: 
Purpose Temp. Time Cycles 
 Initial denaturation 95 °C 10 min 1 
 Denaturation 95 °C 15 s  
Annealing+extension 60 °C 60 s 40 
 
 
 
5x First-strand buffer 4 µl 
0.1 M DTT 2 µl 
Mix contents gently. Incubate at 25 ᵒC for 2 mins. 
Add 1 µl (200 units) Superscript TM III and mix gently. 
Incubate at 25 ᵒC for 10 min and 45 ᵒC for 50 mins. 
Inactivate the reaction by heating at 70 ᵒC for 15 mins.  
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 Statistics 
 
At least, 4 animals were included for gene expression analysis by RT-PCR. Cell 
and myelin quantifications by IHC for cuprizone treated animals were performed 
for at least 5 animals/group and 2-3 slides per animal. 6 animals per group were 
included for chEAE experiments and the corresponding quantifications with 2-3 
slides per animal and spinal cord.  
All data are given as means ± SEM. Statistical differences between various 
groups were analyzed by one-way analysis of variance (ANOVA) followed by 
Tukey’s post-hoc test. Differences between 2 groups were analyzed by Stu-
dent’s t test. De-remyelination scores were analyzed by nonparametric meth-
ods, Kruskal-Wallis or Mann-Whitney tests. Statistical analysis was performed 
using GraphPad Prism 5 (GraphPad software Inc., USA). Statistical significance 
was set at p<0.05. 
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4 Results 
 Smpd1 deficiency prevents chEAE symptoms and demyelination 
 
To determine whether acid sphingomyelinase plays a role in chEAE, Smpd1    
genetically deficient mice and corresponding WT littermates were immunized 
with MOG33-55 and scored daily till 45 days post immunization; symptoms were 
recorded according to a - scale from 0 to 5 as mentioned in section 3.2.2.3 
(Fig.8). 
 
Figure 6:  Genetic Smpd1 deficiency prevents chEAE symtomps and demyelination. 
chEAE was induced in Smpd1-/- mice and corresponding C57BL/6J wild-type littermates, 
chEAE symptoms were scored daily on a scale from 0 to 5. Smpd1-/- showed no clinical 
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score compared to wild types (A). LFB staining of the isolated spinal cords after 45 days 
of disease course revealed that no demylination or infiltration occurred in Smpd1-/- mice 
compared to wild type animals (B). Lesion numbers and inflammation score was 
recorded, a significant difference was observed between Smpd1-/-     and wild-types mice 
(C). ***p˂0.001 Smpd1-/-  vs wild-type . Scale bar 50 µm. 
Smpd1 genetically deficient mice showed no chEAE symptoms through the 45 
days duration post immunization with a clinical score of 0 during the whole stud-
ied period. On the other hand, wild-type littermate mice got sick and showed 
disease symptoms during the same duration with a clinical score ranging be-
tween 0.5 and 3.  
To investigate the degree of demyelination, spinal cord sections were stained 
using luxol fast blue and revealed no demyelination in Smpd1-/- mice compared 
to wild-type littermates. To assess lesion numbers and inflammation a scoring 
system was applied as detailed in section 3.7.  Smpd1-/- mice showed a signifi-
cantly lower number of lesions and inflammation score compared to chEAE 
wild- type littermates (Fig. 8c and 8d).  
As negative controls, spinal cords isolated from both Smpd1-/- and wild-type 
mice without chEAE induction demonstrated no lesions and no inflammation. 
 T cell infiltration to the CNS is inhibited by Smpd1 deficiency   
 
Demyelination and neurodegeneration in MS are direct causes of inflammatory 
activation (Henderson at al., 2009), based on that at day 45 post immunization 
Smpd1-/- and corresponding wild-type littermates were sacrificed and IHC 
against CD3 was performed to investigate the effects of Smpd1-/- on neuroin-
flammatory activation and T cell recruitment to the CNS (Fig. 9a).  
Smpd1-/- mice significantly inhibited infiltration of T lymphocytes in the spinal 
cord, as demonstrated by significantly fewer CD3+ cells in Smpd1-/-  mice com-
pared to wild-type chEAE mice (Fig. 9b).  
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Figure 7: Genetic Smpd1 deficiency inhibits lymphocyte infiltration to the spinal cord. 
chEAE Smpd1-/-   and C57BL/6J wild-type littermate spinal cord sections stained using 
IHC against CD3 antibody (A). Smpd1-/-   mice significantly reduced T cell infiltration into 
the CNS (B). Negative control not immunized Smpd1-/-   and wild-type animals show little 
to none T cells in the spinal cords. **p˂0.01 Smpd1-/-  vs wild-type. Scale bar 50 µm. 
 
 Smpd1 deficiency significantly decreases astrogliosis and mi-
crogliosis  
 
Reactive astrocytes surround plaques forming astrocytic scars blocking the re-
covery in MS (Kuhlmann et al., 2008). Microglia as well plays a significant role 
in the intensity of neuroinflammation (Heppner FL et al., 2005).  
IHC, antibodies against GFAP and Iba-1 markers for astrocytes and microglia 
respectively (Fig. 10a) were applied to study the effect of Smpd1 deficiency on 
astrogliosis and microgliosis in chEAE. Cell count was performed in spinal cord 
of chEAE animals, Smpd1-/-  mice showed a significant decrease in both astro-
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gliosis and microgliosis compared to wild-type chEAE littermates (Fig. 10b and 
10c).  
 
Figure 8: Smpd1 deficiency significantly decreases astrogliosis and microgliosis in 
chEAE compared to C57BL/6J littermates. Spinal cord histopathology was performed at 
day 45 of chEAE using antibodies against GFAP and Iba-1. Wild-type chEAE mice 
showed a significantly higher number of astrocytes and microglia in the spinal cord 
compared to chEAE Smpd1-/-   animals (A). GFAP+ and Iba-1 + cells with positive nuclei 
were counted and quantified in the spinal cords in an area not less than 11x106 µm. Both 
GFAP+ and Iba-1+ cell number were significantly lower in Smpd1-/- mice compared to 
wild-type (B). ***p˂0.001  and **p˂0.01 Smpd1-/-   vs wild-type. Scale bar 50 µm 
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 Pharmacological inhibition of ASM by amitriptyline attenuates 
chEAE symptoms, astrogliosis and microgliosis  
 
As a potential therapeutic option, we studied whether the inhibition of ASM us-
ing amitriptyline would reveal same results as genetic Smpd1 deficiency. Wild- 
type chEAE mice and corresponding littermates were treated with amitriptyline 
or PBS at the detection of weight loss, days 12-14 post immunization for 6 days 
in a bi-daily manner. chEAE animals were scored daily during the duration of 
the 45 days, a significant attenuation of chEAE symptoms was observed after 
the inhibition of ASM in amitriptyline treated animals compared to mice receiv-
ing only PBS (Fig. 11a).  
 
 
 Figure 9: Pharmacological inhibition of ASM significantly decreases chEAE symptoms 
and demyelination. C57BL/6J and corresponding littermates were immunized, treated 
with amitriptyline or PBS as control, and scored for chEAE symptoms till day 45. Amitrip-
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tyline treatment significantly attenuated chEAE compared to animals treated with PBS 
(A). The inhibition of ASM by amitriptyline showed a significant decrease in lesion num-
ber and inflammation score compared to control, observed in LFB stained spinal cord 
section at day 45 of chEAE (B and C). ***p˂0.001 , amitriptyline treated vs PBS  Wild-type. 
Scale bar 50 µm. 
LFB staining revealed significant decrease in both lesion numbers and inflam-
mation score in the amitriptyline treated groups compared to PBS treated ani-
mals (Fig. 11b, 11c and 11d).  
 
Figure 10: ASM inhibition by amitriptyline stops T cell infiltration and significantly lowers 
astrogliosis and microgliosis in chEAE. At day 45 of chEAE spinal cords from C57BL/6J 
amitriptyline treated and controls,  were isolated, processed and stained against CD3 (T-
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cells), GFAP (astrocytes) and Iba-1 (microglia) (A). Positive cells with visible nuclei were 
counted and quantified (B). Inhibition of ASM by amitriptyline significantly decreased T 
cell infiltration to the CNS compared to PBS controls as demonstrated by CD3+ cell 
numbers in the spinal cords of chEAE mice. Astrogliosis and microgliosis in amitripty-
line treated chEAE animals were significantly lower compared to PBS treated wild-types 
chEAE mice. **p˂0.01 and *p˂0.05 amitriptyline treated chEAE vs PBS chEAE wild-types. 
Scale bar 50 µm 
 
Immunohistochemistry against CD3 was used for the detection of lymphocyte 
infiltration in the spinal cord of chEAE mice and revealed a significant decrease 
in T cell infiltration after the inhibition of ASM compared to PBS treated chEAE 
animals (Fig. 12a and 12b).  
ASM inhibition by amitriptyline not only lowered T cell numbers in the spinal 
cord of chEAE mice, but also significantly decreased neuroinflammation in the 
CNS demonstrated by lower astrocyte and microglia numbers (Fig. 12c and 
12d).  
Negative control animals not immunized and untreated showed no T cell infiltra-
tion to the spinal cord nor astrogliosis or microgliosis. 
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 Smpd1 deficiency enhances myelin recovery after acute and 
chronic demyelination 
 
Cuprizone treatment for 5 (acute) or 12 (chronic) weeks causes significant de-
myelination with the potential to recover after drug deprivation. In order to inves-
tigate the role of Smpd1 in this process, the extend of demyelination was 
 
Figure 11: Brain sections were stained for LFB and MBP. Cuprizone treatment for 5 
weeks or 12 weeks causes a massive decrease in myelination as determined by LFB and 
MBP staining in the CCm (a). Smpd1-/-  mice showed a significant remyelination compared 
to C57BL/6J wild-type littermates after 2 weeks of recovery period weeks 7 and 14, de-
termined by the quantification of myelination score (b) and MBP fluorescence intensity in 
the CCm (c). *p˂0.05 Smpd1-/-   vs wild-type remyelination weeks 7 and 14. Scale bar, 100 
µm.  
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immunohistochemically displayed by LFB-PAS and myelin basic protein staining 
(Fig. 13a) and of axonal damage by APP and synaptophysin analysis (Fig. 14) 
in the midline of the corpus callosum (CCm), one characteristically affected 
brain region in the cuprizone mouse model (Kuhlmann et al., 2002; Skripuletz et 
al., 2012; Kipp et al., 2009; Pfeifenbring et al., 2015). Smpd1  deficiency signifi-
cantly restored myelin formation after a 2 week recovery phase following acute-
and chronic cuprizone treatment (Fig. 13b and 13c). 
In addition, axonal damage was significantly reduced in Smpd1 deficient mice 
compared to wild-type littermates, in the recovery phase after acute, but not 
chronic demyelination (Fig. 14b and 14c).  Olig-2 is a cellular oligodendrocyte 
marker, strongly expressed by oligodendrocyte precursor cells (OPCs) and only 
weakly by mature oligodendrocytes (Kuhlmann et al., 2008).  
Corresponding to the previous data, a significant increase in oligodendrocytes 
proliferation was detected after recovery from both, acute and chronic cuprizone 
treatment in the CCm of Asm deficient animals compared to wild-type mice 
(Fig. 14e and 14d). 
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Figure 12 : Axonal damage analysis with IHC. Staining for APP and synaptophysin in the 
CCm of wild-type and Smpd1-/-   animals after acute or chronic cuprizone treatment fol-
lowed by 2 weeks recovery period week 7 and week 14 respectively (a). Smpd1-/-   mice 
showed significantly lower damaged axons in the acute treated groups followed by 2 
weeks remyelination compared to wild-type mice (b, c). This difference was not signifi-
cant after the 12 weeks treatment of cuprizone followed by 2 weeks recovery period. ** 
p˂0.01 and *p˂0.05 Smpd1-/-   vs wild-type. Scale bar, 50 µm. IHC revealed a significant 
increase in Olig-2+ cell numbers in Smpd1-/-   mice compared to wild-type after acute or 
chronic cuprizone treatment followed by 2 weeks recovery period week 7 and 14 respec-
tively (d,e).  *p˂0.05 Smpd1-/-  vs wild-type. Scale bar, 100 µm. The effect of Smpd1 gene 
deficiency during the 2 weeks recovery after 5 weeks cuprizone feeding (week 7) on 
mRNA expression levels of different growth factors was analyzed. FGF1 and FGF2 mRNA 
levels were significantly increased in Smpd1-/-    mice compared to wild-type PBS treated 
(f, g). *p˂0.05 Smpd1-/-   vs wild-type 
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Myelin growth has been shown to be controlled by fibroblast growth factors 
(FGF) (Furusho et al., 2012; Mohan et al., 2014). Therefore, FGF-1 and -2 m 
RNA levels were analysed. Smpd1  deficient mice showed a significant increase 
of FGF-1 and -2 compared to wild-type littermates after the 2 week recovery 
phase following acute demyelination, hinting towards improved myelin regener-
ation (Fig. 14f and 14g). 
Irrespective, we did not detect any difference in the degree of demyelination or 
axonal damage direct after 5 or 12 weeks cuprizone treatment without time to 
recover (Fig. 13b, 13c and 14b 14c).  
 
 Smpd1 deficiency reduces astrogliosis and production of in-
flammatory cytokines after acute demyelination  
 
Glial cells, especially astrocytes have been discussed to play a dual role in 
myelin disorders. Beside their synaptic stabilizing function, they can also pro-
mote inflammatory reactions with subsequent myelin and axonal damage.   
Therefore, we investigated glial cell proliferation by immunohistochemistry and 
production of respective inflammatory markers by real-time PCR.  The result 
showed a significant reduction in astrocyte cell numbers and astrocytic activa-
tion, displayed by GFAP staining intensity, in Smpd1 deficient animals com-
pared to wild-type littermates after the 2 week recovery phase following 5 weeks 
of cuprizone treatment (Fig. 15a, 15c and 15d).   
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Figure 13: Effect of Smpd1-/-   on astrogliosis and microgliois. The effect of Smpd1-/-  on 
astrogliosis (a) and microgliois (b) in the CCm after 5 or 12 weeks cuprizone treatment 
followed by 2 weeks remyelination. IHC revealed a significant decrease of GFAP+ cells 
and GFAP staining intensity in Smpd1-/-   compared to C57Bl/6J mice after 5 weeks of cu-
prizone treatment followed by 2 remyelination, week 7 (c, d). Smpd1 knockout has no 
effect on microgliosis neither in acute nor in chronic groups (e, f).  *p˂0.05 Smpd1-/-     vs 
C57BL/6J. Scale bar, 100 µm. Smpd1 deficiency significantly decreased Il-1ß mRNA ex-
pression levels compared to wild-type PBS treated animals (g) after 5 weeks cuprizone 
treatment followed by 2 weeks recovery. mRNA expression levels of Mrc-1 showed no 
significant difference between the compared groups (h). *p˂0.05 Smpd1 deficient vs 
C57Bl/6J wild-types. 
 
This difference was not observable after chronic demyelination (Fig. 15c and 
15d). Correspondingly, a significant decrease of pro-inflammatory interleukin-1β 
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(IL-1β) mRNA levels could be detected in Smpd1deficient animals compared to 
wild-type littermates (Fig. 15g). 
As demonstrated in Fig. 17b, e and f, Smpd1 deficient mice neither showed any 
difference in the number or staining intensity of Iba-1 positive microglial cells 
nor in mRNA expression of Mrc-1 (Fig. 15h), a marker correlating to anti-
inflammatory M2 microglia phenotype (Röszer 2015). Non-cuprizone treated 
healthy control mice only showed few astrocytes or microglia in the CCm (Fig. 
15c and 15e). 
 Pharmacological inhibition of ASM as therapeutic option for 
myelin repair 
 
To elaborate a potential therapeutic approach, the effect of pharmacological 
inhibition of ASM  by amitriptyline was investigated in wild-type littermate mice in  
Figure 14: Brain sections stained for LFB and MBP. The representative brain sections 
stained for LFB (a) and MBP (b) are shown in the CCm of control and amitriptyline treated 
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mice. The extent of de- and remyelination was judged by scoring LFB stained brain sec-
tion and quantifying MBP intensity of the CCm in control and treated animals. The inhibi-
tion of ASM by amitriptyline significantly restored myelin compared to PBS treated ani-
mals after 5 weeks cuprizone treatment followed by 2 weeks of recovery (c, d).***p˂0.001 
and *p˂0.05 Amitriptyline treated vs PBS. Scale bar, 100 µm. 
 
the acute cuprizone model. Therefore, 5 week cuprizone treatment was fol-
lowed by the 2 week recovery period, during which amitriptyline injections or 
PBS injections were administered twice daily.  
The inhibition of ASM  by amitriptyline showed a significantly higher myelin re-
covery in the CCm compared to animals treated with PBS as revealed by LFB 
and MBP intensity (Fig. 16). Axonal damage in the CCm of animals treated with 
amitriptyline was significantly decreased compared to PBS treated mice (Fig. 
17a, 17b and 17c) as assessed by APP positive neurons and synaptophysin 
positive buds. 
Concerning the groups mentioned in section 3.2.3, the differences between 
Smpd1-/- and C57BL/6J wild-type littermate mice in the 5 weeks demyelination 
groups and the 1 week remyelination were not significantly different (data not 
shown). 
In addition, Olig-2+ cell numbers in amitriptyline-treated animals were signifi-
cantly increased compared to the PBS treated mice after 2 weeks of recovery 
(Fig. 17d and 17e) and myelin growth factors FGF-1 and -2 showed an in-
creased mRNA level after amitriptyline treatment (Fig. 17f and 17g).   
Untreated control animals did not show any APP or synaptophysin positive 
buds, no axonal damage was observed (Fig. 17b and 17c). 
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Figure 15: Stainings for APP and synaptophysin IHC staining for APP and synaptophysin 
in the CCm of amitriptyline or PBS treated animals during the 2 weeks recovery after 5 
weeks of cuprizone treatment (a). ASM inhibition by amitriptyline showed significantly 
lower axonal damage, as demonstrated by APP and Synaptophysin positive buds in the 
CCm (b, c).  **p˂0.01 and ***p˂0.001 amitriptyline treated vs PBS treated mice. Scale bar, 
50 µm. IHC revealed a significant increase of Olig-2+ cells in the CCm of amitriptyline 
treated mice compared to PBS treated (d, e).  mRNA expression levels of FGF-1 and FGF-
2 mRNA levels were significantly increased in amitriptyline treated mice compared to 
PBS controls (f, g). **p˂0.01 and *p˂0.05 amitriptyline treated vs PBS treated. 
Corresponding to previous results, one effect of ASM inhibition by amitriptyline 
was a reduction of the detrimental astrocytosis. Amitriptyline mice showed a 
significant reduction in astrocyte cell numbers and GFAP staining intensity in 
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the CCm compared to PBS treated animals (Fig. 18c and 18d) as well as sig-
nificant lower levels of the inflammatory cytokines IL-1β (Fig. 18g). Again, there 
was no difference in microglial cell numbers (Fig. 18e and 18f). 
  
Figure 16: Astrogliosis and microgliosis after amitriptyline treatment. ASM inhibition by 
amitriptyline for 2 weeks of recovery period after 5 weeks cuprizone feeding effects as-
trogliosis and microgliosis in the CCm (a,b).  IHC revealed a significant decrease of 
GFAP+ cells and GFAP staining intensity of the CCm in the amitriptyline treated group 
compared to PBS treated (c, d). Iba1 + cell numbers and iba1 staining intensity in the 
CCm of amitriptyline or PBS treated animals showed no significance difference (e, f). 
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**p˂0.01 amitriptyline treated vs PBS treated groups. Scale bar, 100 µm. The Inhibition of 
ASM by amitriptyline did significantly decrease Il-1ß mRNA expression levels compared 
to wild-type PBS treated animals during the 2 weeks recovery after 5 weeks cuprizone 
treatment (g), while mRNA expression levels of Mrc-1 showed no significant difference 
between the compared groups (h). *p˂0.05 amitriptyline treated vs PBS treated mice. 
 
 
5 Discussion 
 
MS is a chronic inflammatory disease of the CNS characterized by inflammatory 
infiltrates, demyelination and axonal loss. It is the most frequent cause of neuro-
logical disability in young adults (Lassmann et al., 2011). The invasion of lym-
phocytes leads to a subsequent myelin loss, astrocyte and microglia activation 
and oligodendrocyte apoptosis. Recovery and remyelination are challenged by 
several factors such as the blockage of the proliferation and differentiation of 
OPCs required to repair damaged myelin (Gudi et al., 2014).   
In this study, we demonstrate that genetic or pharmacological inhibition of acid 
sphingomyelinase activity protects against chEAE, lowering lymphocyte infiltra-
tion to the CNS, glia activation and neuroinflammation. Also, Smpd1 deficiency 
enhances myelin repair after acute or chronic experimental demyelination by 
lowering astrocytosis and with a significant increase of oligodendrocyte prolifer-
ation. Thus, acid sphingomyelinase plays a crucial role in the pathophysiology 
of MS both acting on T cell transmigration and enhancing remyelination by indi-
rect effect on astrocytes and increased oligodendrocyte proliferation and differ-
entiation. Thus, the ASM/ceramide system can enhance remyelination and re-
covery after cuprizone induced demyelination. 
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 Acid sphingomyelinase deficiency in chEAE pathophysiology 
 
The sphingomyelin pathway is crucial for maintaining cell integrity and cell func-
tion. Enzymes involved in this pathway like acid sphingomyelinase are present 
throughout the brain. The present study indicates a strong link between acid 
sphingomyelinase and the pathogenesis of MS. In MS as well as in a chEAE 
model, autoimmune reactive T cells from the periphery invade the CNS leading 
to neuroinflammation, demyelination and neurodegeneration (Lassmann et al., 
2011).  
In this study, we showed that Smpd1 deficient mice showed attenuated chEAE 
symptoms accompanied with lower neuroinflammatory activation. In contrast, 
chEAE wild-type littermates were consistently sick showing significantly higher 
clinical scores. ASM and its enzymatic product ceramide have both been shown 
to be highly expressed in active human MS lesion (van Doorn et al., 2010) re-
porting a role of ASM in MS pathology. We documented that mice lacking clini-
cal disease scores were also free from inflammatory infiltrates, correlating his-
tology results with clinical score. Inflammation and lesion formation is strongly 
correlated with disease severity (Recks et al., 2011). We demonstrated with 
CD-3 immunostaining that Smpd1 deficient mice showed significantly lower 
number of T cells in the CNS of chEAE animals, pointing toward a direct role of 
Smpd1 activity in T cell infiltration in chEAE. These results suggest an important 
role of the ASM/ceramide system in the development of chEAE and leukocyte 
infiltration to the CNS. This corresponds to the study by Lopes et al. (2016), re-
porting Asm expression in inflamed brain vasculature and the role of ASM in 
transmigration process of T cells into the CNS under inflammatory conditions 
like MS. Lopes et al., suggested that ASM activity controls proper ICAM-1 clus-
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tering, hence providing a perfect actin network across which T cells can adhere 
and transmigrate invading the CNS.  
Reactive astrocytes surround plaques forming astrocytic scars blocking recov-
ery in MS. Microglia has a significant role in the intensity of neuroinflammation 
(Kuhlmann et al., 2008; Heppner et al., 2005). Cell counts for both GFAP and 
iba-1 markers of astrocytes and microglia respectively, were significantly lower 
in immunized Smpd1 deficient mice compared to wild-type littermates. The inhi-
bition of Smpd1 activity stops T cell infiltration to the CNS, which in turn could 
affect the degree of neuroinflammation consisting of astrocyte and microglia 
activation. 
 Pharmacological inhibition of ASM in chEAE 
Amitriptyline, as well as other functional inhibitors of acid sphingomyelin (FIAS-
MA’s) drugs, acts by competitive inhibition of ASM (Kornhuber et al., 2010). It 
inhibits around 60% to 80% of ASM activity (Teichgraber et al., 2008; Beck-
mann 2014). In this study we show that treatment with amitriptyline significantly 
reduces clinical scores in chEAE animals, consisting with our results in Smpd1 
genetically deficient mice. Amitriptyline reduced T cell infiltration to the CNS 
demonstrated by CD-3 staining; in addition cell counts for astrocytes and micro-
glia were significantly lower compared to PBS treated chEAE mice. Our data 
suggest that amitriptyline inhibition of ASM activity corresponds to the results 
found in Smpd1 genetically deficient mice with lower neuroinflammation and 
glial activation. Thus, given the long-term experience and clinical safety of ami-
triptyline and the present results in chEAE, amitriptyline could be a promising 
candidate for MS patients. A clinical study of MS patients treated with fluoxe-
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tine, another FIASMA, has already shown a reduction in MRI lesion progression 
(Mostert et al., 2008; Davies, 2013).   
 Acid sphingomyelinase deficiency in de- and remyelination 
The results of this study demonstrate that genetic deficiency or pharmacological 
inhibition of the Asm/ceramide system can enhance myelin repair after cu-
prizone induced demyelination. By deficiency of the Asm/ceramide system, we 
could observe a significantly improved recovery of myelin as indicated by MBP 
and LFB intensity scores and an increase in oligodendrocyte proliferation as 
indicated by increased Olig-2 positive cells in the recovery phase after cu-
prizone treatment. This led to a reduction of neuronal damage. Interestingly, 
MBP/LFB levels and Olig-2 positive cell numbers were close to normal values of 
completely untreated mice. This is in accordance with the observation that 
ceramide has been shown to induce oligodendrocyte cell death together with 
the pro-inflammatory cytokine tumor necrosis factor alpha in human MS brains. 
In addition, overexpression of ASM and subsequent increase of ceramide re-
sulted in reduced neuronal survival even without any further cell stress (Kim 
Hye et al., 2011; Kim SunJa et al., 2012; Gulbins et al., 2013).  
Fibroblast growth factors are important drivers of myelination (Mohan et al., 
2014; Furusho et al., 2012; Messersmith et al., 2000). Further supporting the 
beneficial effect of ASM/ceramide deficiency, FGF1 and FGF2 showed a signifi-
cant increase in the recovery phase after acute demyelination. Activation of 
CNS cells, especially astrocytes, is discussed as important mechanism in MS 
associated de- and remyelination. Astrocytes can show a dual role with either 
beneficial functions by facilitating e.g. microglial-mediated myelin clearance (T. 
Skripuletz et al., 2012) or detrimental functions by enhancing inflammatory mye-
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lin toxic reactions by e.g. inflammatory cytokine production (Gudi et al., 2014).  
ASM-induced ceramide is the principle component of ceramide-enriched mem-
brane platforms, which are a pre-requisite for full cell activation facilitating 
membrane receptor assembling and subsequent intracellular signalling with 
possible thunder storm of pro-inflammatory mediators (Gulbins and Li, 2006). 
In the current study, as consequence of the Smpd1 genetic deficiency and sub-
sequent reduced ceramide level, a significant reduction of activated astrocytes 
and the pro-inflammatory cytokine IL-1β could be observed and might act as 
potential mechanism for the optimized myelin repair. However, astrocyte num-
bers in Smpd1 deficient mice are significantly, but only 30%, reduced compared 
to wild-type littermates. This is important as a complete ablation of astrocytes 
leads to a deprivation of their beneficial functions (Skipuletz et al., 2013). The 
observed differences upon Smpd1 deficiency were seen in the recovery phase 
after acute demyelination with 5 weeks of cuprizone treatment, hinting towards 
an involvement of glial cells mainly after acute myelin injury. Recovery after 
chronic demyelination (12 weeks of cuprizone) resulted in a still increased mye-
lin content and oligodendrocyte proliferation, but did not show a clear glial cell 
involvement.  There was also no difference in the extent of acute or chronic 
demyelination directly after 5 or 12 weeks of cuprizone treatment, indicating an 
equal mode of action of cuprizone in both, Smpd1 genetically deficient mice or 
wild-type littermates and further demonstrating a relevant effect of the 
Asm/ceramide system in promotion of remyelination rather than augmentation 
of demyelination. 
Microglia are reported to play a supportive role in remyelination (Gudi et al., 
2014). In the cuprizone animal model, they act as marker for drug-induced pa-
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thology and are increased and activated after cuprizone treatment (Goldberg et 
al., 2015). Interestingly, we did not see any difference in these increased micro-
glia cell numbers or in their activation in Smpd1 deficient versus wild-type litter-
mates in the recovery after acute demyelination, excluding any important role of 
microglia in myelin repair.  
 Pharmacological inhibition of acid sphingomyelinase and mye-
lin repair 
As potential therapeutic approach to support remyelination, we could show that 
the positive effect of Smpd1 deficiency in myelin recovery can be mimicked by 
treatment with amitriptyline, a well-known pharmacological Acid sphingomye-
linsae inhibitor (Kornhuber et al., 2010). Amitriptyline treatment was only initiat-
ed after cuprizone-induced myelin damage and was able to restore MBP and 
LFB intensity to normal values after 2 weeks with an even higher than normal 
level of oligodendrocyte proliferation. Again astrocytes were inhibited as poten-
tial mechanism for neuronal repair. These results strongly hint towards a detri-
mental role of the ASM/ceramide system not during myelin damage but during 
potential repair mechanisms.  
We show that ASM/ceramide deficiency or amitriptyline-induced pharmacologi-
cal inhibition enhance remyelination after acute and chronic myelin damage. As 
potential mechanism a reduction in astrocyte proliferation and activation with 
reduced pro-inflammatory cytokine release, resulting in enhanced oligodendro-
cyte proliferation and neuronal preservation could be observed.  
We show the effects of acid sphingomyelinase genetic deficiency or its pharma-
cological inhibition in two animal models of MS. In the chEAE animal model, 
ASM was reported to have a crucial effect on T cell infiltration to the CNS, and 
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to stop disease severity in chEAE mice, correlating with recent studies conduct-
ed in vitro (Lopes et al., 2016). Microgliosis and astrogliosis in Smpd1 deficient 
mice were also significantly decreased in chEAE model; this might be due to the 
lower and near to none T cell infiltration of the CNS in Smpd1 deficient mice, 
which in turn did not activate microglia and astrocytes. This observation is in 
contrast to what was observed in chEAE wild-type mice with a high degree of 
neuroinflammation. In an effort to translate the corresponding findings, amitrip-
tyline, a known inhibitor of ASM and a widely used anti-depressant, was inject-
ed in wild-type chEAE mice. The pharmacological inhibition of ASM corre-
sponded with the results reported in Smpd1 genetically deficient mice. Thus, it 
might be that ASM-ceramide system would be an important therapeutic target in 
MS.  
In the second animal model of MS, the toxic demyelination model, we wanted to 
investigate the role of acid sphingomyelinase both in demyelination and as well 
as in the remyelination phase. During demyelination no results suggested any 
significant role for acid sphingomyelinase, results showed no significance differ-
ence between Smpd1 genetically deficient mice and wild-type mice. In contrast 
to demyelination, in remyelination we reported a significance difference in mye-
lin repair after two weeks of the cuprizone withdrawal with increased oligoden-
drocyte proliferation in the Smpd1 deficient mice compared to wild-type litterma-
tes. 
 Hence, our data points towards an important role of acid sphingomyelinase in 
the remyelination phase both after acute and chronic demyelination. To further 
investigate and to confirm the role of ASM, we used the functional inhibitor ami-
triptyline in the 2 weeks recovery phase after cuprizone withdrawal to study 
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whether the pharmacological inhibition of amitriptyline could yield to similar re-
sults as obtained from the Smpd1 deficient mice in the cuprizone model. Ami-
triptyline injected mice in the recovery phase showed a significant myelin repair 
compared to mice injected with PBS at the same period and phase of recovery. 
With results corresponding to the genetic deficiency of Smpd1, increased oli-
godendrocte proliferation was documented with a lower degree of astrocyte ac-
tivation. 
Since the BBB remains intact in the cuprizone model we excluded the effect of 
acid sphingomyelinase on T cells in the toxic demyelination model, and focused 
our interest on the glial cells. As documented ASM inhibition did significantly 
decrease astrogliosis in the 2 weeks recovery phase with a higher oligodendro-
cyte proliferation and differentiation, but did not show any effect on microgliosis.  
Might be that it is affecting the remyelination pathway which microglia does not 
have a crucial role in. Certainly, the 30% decrease in astrogliois compared to 
that of wild-type has a beneficial effect on remyelination as was suggested be-
fore that astrocytes troubles remyelination in chronic MS by inhibiting OPCs 
proliferation and differentiation. Therefore, the inhibition of acid sphingomyelin-
ase enhanced remyelination by an in-direct effect on astrocytes and oligoden-
drocyte proliferation.  
We show that the ASM-Ceramide system plays an important role in T cell infil-
tration in the chEAE model, stopping disease severity and neuroinflammation 
reporting the role of ASM on T cell transmigration in vivo. Also we report the 
role of ASM in remyelination showing enhanced myelin recovery after acute and 
chronic demyelination. With respect to these findings ASM-ceramide system 
might be a therapeutic option for MS patients. 
Sphingolipids in MS 
 
71 
 
6 References  
 
Armstrong RC, Le TQ, Frost EE, Borke RC, Vana AC (2002) Absence of fibroblast 
growth factor 2 promotes oligodendroglial repopulation of demyelinated white 
matter. Journal of Neuroscience 22:8574-8585 
Artemiadis AK, Anagnostouli MC (2010) Apoptosis of Oligodendrocytes and Post-
Translational Modifications of Myelin Basic Protein in Multiple Sclerosis: 
Possible Role for the Early Stages of Multiple Sclerosis. European Neurology 
63:65-72 
Bakker DA LS (1987) Blood-brain barrier permeability during cuprizone induced 
demyelination. Implication for the pathogenisis of immune-mediated 
demyelinatind diseases. J Neurol Sci 78:125-137 
Barnett MH PJ, Pollard JD, Prineas JW (2009) MS: is it one disease? Int MS J 16:57-
65 
Beckmann N, Sharma D, Gulbins E, Becker KA, Edelmann Br (2014) Inhibition of acid 
sphingomyelinase by tricyclic antidepressants and analogons. Frontiers in 
Physiology 5 
Bianco F, Perrotta C, Novellino L, Francolini M, Riganti L, Menna E, Saglietti L, 
Schuchman EH, Furlan R, Clementi E, Matteoli M, Verderio C (2009) Acid 
sphingomyelinase activity triggers microparticle release from glial cells. The 
EMBO Journal 28:1043-1054 
Blackmore (1972) Observations on oligodendrocyte degeneration, the resolution of 
status spongiosus and remyelination in cuprizone intoxication in mice. Journal 
of Neurocytology  I: 413-426  
Britta Engelhardt DV, Rupert Hallmann, Martina Schulz (1997) E- and P-Selectin Are 
Not Involved in the Recruitment of Inflammatory Cells Across the Blood-Brain 
Barrier in Experimental Autoimmune Encephalomyelitis. Blood 90:4459-4472 
Brown GC (2007) Mechanisms of inflammatory neurodegeneration: iNOS and NADPH 
oxidase. Biochemical Society Transactions 35:1119-1121 
Brunkhorst R, Vutukuri R, Pfeilschifter W (2014) Fingolimod for the treatment of 
neurological diseases state of play and future perspectives. Frontiers in Cellular 
Neuroscience 8 
Bush TG, Puvanachandra N, Horner CH, Polito A, Ostenfeld T, Svendsen CN, Mucke 
L, Johnson MH, Sofroniew MV (1999) Leukocyte infiltration, neuronal 
degeneration, and neurite outgrowth after ablation of scar-forming, reactive 
astrocytes in adult transgenic mice. Neuron 23:297-308 
Sphingolipids in MS 
 
72 
 
Chen H, Tran J-TA, Brush RS, Saadi A, Rahman AK, Yu M, Yasumura D, Matthes MT, 
Ahern K, Yang H, LaVail MM, Mandal MNA (2012) Ceramide Signaling in 
Retinal Degeneration.  723:553-558 
Chhor V, Le Charpentier T, Lebon S, Oré M-V, Celador IL, Josserand J, Degos V, 
Jacotot E, Hagberg H, Sävman K, Mallard C, Gressens P, Fleiss B (2013) 
Characterization of phenotype markers and neuronotoxic potential of polarised 
primary microglia in vitro. Brain, Behavior, and Immunity 32:70-85 
Choi JW, Chun J (2013) Lysophospholipids and their receptors in the central nervous 
system. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of 
Lipids 1831:20-32 
Compston A, Coles A (2002) Multiple sclerosis, Vol 359 
Correale J, Villa A (2009) Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple 
sclerosis. Annals of Neurology:n/a-n/a 
Davies L (2013) The Role of Acid Sphingomyelinase in Experimental Autoimmune 
Encephalomyelitis. 
Ferlinz RH, Gabriele V, Kunihiko S et al., (1994) Occurrence of two molecular forms of 
human acid sphingomyelinase. Biochem J 301:855-858 
Furusho M, Dupree JL, Nave KA, Bansal R (2012) Fibroblast Growth Factor Receptor 
Signaling in Oligodendrocytes Regulates Myelin Sheath Thickness. Journal of 
Neuroscience 32:6631-6641 
Gandhi R, Laroni A, Weiner HL (2010) Role of the innate immune system in the 
pathogenesis of multiple sclerosis. Journal of Neuroimmunology 221:7-14 
Gatt S (1963) Enzymic Hydrolysis and Synthesis of Ceramides. Journal of Biological 
Chemistry 238:3131- 
Gol M, Ghorbanian D, Hassanzadeh S, Javan M, Mirnajafi-Zadeh J, Ghasemi-Kasman 
M (2017) Fingolimod enhances myelin repair of hippocampus in 
pentylenetetrazol-induced kindling model. European Journal of Pharmaceutical 
Sciences 96:72-83 
Gold R. HH, Toyka KV (2000) Animal models for autoimmune demyelinating disorders 
of the nervous system. Mol Med Today 6:88-91 
Goldberg J, Clarner T, Beyer C, Kipp M (2015) Anatomical Distribution of Cuprizone-
Induced Lesions in C57BL6 Mice. Journal of Molecular Neuroscience 57:166-
175 
Goncalves DaSilva A, Yong VW (2009) Matrix Metalloproteinase-12 Deficiency 
Worsens Relapsing-Remitting Experimental Autoimmune Encephalomyelitis in 
Association with Cytokine and Chemokine Dysregulation. The American Journal 
of Pathology 174:898-909 
Sphingolipids in MS 
 
73 
 
Gudi V (2010) Regional differences of molecular factors during demyelination and early 
remyelination in the CNS. 
Gudi V, Gingele S, Skripuletz T, Stangel M (2014) Glial response during cuprizone-
induced de- and remyelination in the CNS: lessons learned. Frontiers in Cellular 
Neuroscience 8 
Gulbins E (2003) Regulation of death receptor signaling and apoptosis by ceramide. 
Pharmacological Research 47:393-399 
Gulbins E, Palmada M, Reichel M, Lüth A, Böhmer C, Amato D, Müller CP, Tischbirek 
CH, Groemer TW, Tabatabai G, Becker KA, Tripal P, Staedtler S, Ackermann 
TF, van Brederode J, Alzheimer C, Weller M, Lang UE, Kleuser B, Grassmé H, 
Kornhuber J (2013) Acid sphingomyelinase–ceramide system mediates effects 
of antidepressant drugs. Nature Medicine 19:934-938 
Gulbins E, Walter S, Becker KA, Halmer R, Liu Y, Reichel M, Edwards MJ, Müller CP, 
Fassbender K, Kornhuber J (2015) A central role for the acid 
sphingomyelinase/ceramide system in neurogenesis and major depression. 
Journal of Neurochemistry 134:183-192 
Haines JL, TerMinassian M, Bazyk A, Gusella JF, Kim DJ, Terwedow H, PericakVance 
MA, Rimmler JB, Haynes CS, Roses AD, Lee A, Shaner B, Menold M, Seboun 
E, Fitoussi RP, Gartioux C, Reyes C, Ribierre F, Gyapay G, Weissenbach J, 
Hauser SL, Goodkin DE, Lincoln R, Usuku K, GarciaMerino A, Gatto N, Young 
S, Oksenberg JR (1996) A complete genomic screen for multiple sclerosis 
underscores a role for the major histocompatability complex. Nature Genetics 
13:469-471 
Henderson APD, Barnett MH, Parratt JDE, Prineas JW (2009) Multiple sclerosis: 
Distribution of inflammatory cells in newly forming lesions. Annals of Neurology 
66:739-753 
Howell OW, Rundle JL, Garg A, Komada M, Brophy PJ, Reynolds R (2010) Activated 
Microglia Mediate Axoglial Disruption That Contributes to Axonal Injury in 
Multiple Sclerosis. Journal of Neuropathology & Experimental Neurology 
69:1017-1033 
Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, Chou YK, Bourdette 
D, Ziegler SF, Offner H, Vandenbark AA (2005) Decreased FOXP3 levels in 
multiple sclerosis patients. Journal of Neuroscience Research 81:45-52 
Jana A, Pahan K (2007) Oxidative stress kills human primary Oligodendrocytes via 
neutral sphingomyelinase: Implications for multiple sclerosis. Journal of 
Neuroimmune Pharmacology 2:184-193 
Sphingolipids in MS 
 
74 
 
Jana A, Pahan K (2010) Sphingolipids in Multiple Sclerosis. NeuroMolecular Medicine 
12:351-361 
Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, Steinman L, Robinson 
WH (2005) Lipid microarrays identify key mediators of autoimmune brain 
inflammation. Nature Medicine 12:138-143 
Paxinos and Franklin (2001) The mouse brain in stereotaxic coordinates. Academic 
press 2 
Kettenmann H, Hanisch UK, Noda M, Verkhratsky A (2011) Physiology of Microglia, 
Vol 91 
Kim HJ, Miron VE, Dukala D, Proia RL, Ludwin SK, Traka M, Antel JP, Soliven B 
(2011) Neurobiological effects of sphingosine 1-phosphate receptor modulation 
in the cuprizone model. The FASEB Journal 25:1509-1518 
Kim S, Steelman AJ, Zhang Y, Kinney HC, Li J (2012) Aberrant Upregulation of 
Astroglial Ceramide Potentiates Oligodendrocyte Injury. Brain Pathology 22:41-
57 
Kipp M, Clarner T, Dang J, Copray S, Beyer C (2009) The cuprizone animal model: 
new insights into an old story. Acta Neuropathologica 118:723-736 
Kornhuber J, Tripal P, Reichel M, Muhle C, Rhein C, Muehlbacher M, Groemer TW, 
Gulbins E (2010) Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): A 
Novel Pharmacological Group of Drugs with Broad Clinical Applications. 
Cellular Physiology and Biochemistry 26:9-20 
Kuhlmann T, Lassmann H, Brück W (2008) Diagnosis of inflammatory demyelination in 
biopsy specimens: a practical approach. Acta Neuropathologica 115:275-287 
Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W (2002) Acute axonal damage 
in multiple sclerosis is most extensive in early disease stages and decreases 
over time. Brain 125:2202-2212 
Lassmann H, Bruck W, Lucchinetti C (2001) Heterogeneity of multiple sclerosis 
pathogenesis: implications for diagnosis and therapy. Trends in Molecular 
Medicine 7:115-121 
Liu, Y., X. Liu, W. Hao, Y. Decker, R. Schomburg, L. Fulop, M. Pasparakis, M. D. 
Menger, and K. Fassbender (2014). "IKK Deficiency in Myeloid Cells Amelio-
rates Alzheimer's Disease-Related Symptoms and Pathology", Journal of Neu-
roscience 
 
Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (1999) A 
quantitative analysis of oligodendrocytes in multiple sclerosis lesions - A study 
of 113 cases. Brain 122:2279-2295 
Sphingolipids in MS 
 
75 
 
Ludwin SK (1980) Chronic demyelination inhibits remyelination in the central nervous 
system. An analysis of contributing factors. Lab Invest 43:382-387 
Hiremath YS, G.W. Knapp, J.P.-Y. Ting,G.K. Matsushima ( 1998 ) Microglial 
rmacrophage accumulation during cuprizone-induced demyelination in C57BL/6 
mice. Journal of Neuroimmunology 92 ;38–49 
Maceyka M, Spiegel S (2014) Sphingolipid metabolites in inflammatory disease. Nature 
510:58-67 
Mason JL, Jones JJ, Taniike M, Morell P, Suzuki K, Matsushima GK (2000) Mature 
oligodendrocyte apoptosis precedes IGF-1 production and oligodendrocyte 
progenitor accumulation and differentiation during demyelination/remyelination. 
Journal of Neuroscience Research 61:251-262 
Matsushima GK, Morell P (2001) The neurotoxicant, cuprizone, as a model to study 
demyelination and remyelination in the central nervous system. Brain Pathology 
11:107-116 
Merson TD, Binder MD, Kilpatrick TJ (2010) Role of Cytokines as Mediators and 
Regulators of Microglial Activity in Inflammatory Demyelination of the CNS. 
NeuroMolecular Medicine 12:99-132 
Messersmith DJ, Murtie JC, Le TQ, Frost EE, Armstrong RC (2000) Fibroblast growth 
factor 2 (FGF2) and FGF receptor expression in an experimental demyelinating 
disease with extensive remyelination. Journal of Neuroscience Research 
62:241-256 
Mi S, Miller RH, Tang W, Lee X, Hu B, Wu W, Zhang Y, Shields CB, Zhang Y, Miklasz 
S, Shea D, Mason J, Franklin RJM, Ji B, Shao Z, Chédotal A, Bernard F, 
Roulois A, Xu J, Jung V, Pepinsky B (2009) Promotion of central nervous 
system remyelination by induced differentiation of oligodendrocyte precursor 
cells. Annals of Neurology 65:304-315 
Miron VE, Hall JA, Kennedy TE, Soliven B, Antel JP (2008a) Cyclical and Dose-
Dependent Responses of Adult Human Mature Oligodendrocytes to Fingolimod. 
The American Journal of Pathology 173:1143-1152 
Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP (2008b) FTY720 
modulates human oligodendrocyte progenitor process extension and survival. 
Annals of Neurology 63:61-71 
Mohan H, Friese A, Albrecht S, Krumbholz M, Elliott CL, Arthur A, Menon R, Farina C, 
Junker A, Stadelmann C, Barnett SC, Huitinga I, Wekerle H, Hohlfeld R, 
Lassmann H, Kuhlmann T, Linington C, Meinl E (2014) Transcript profiling of 
different types of multiple sclerosis lesions yields FGF1 as a promoter of 
remyelination. Acta Neuropathologica Communications 2 
Sphingolipids in MS 
 
76 
 
Mostert JP, Admiraal-Behloul F, Hoogduin JM, Luyendijk J, Heersema DJ, van Buchem 
MA, De Keyser J (2008) Effects of fluoxetine on disease activity in relapsing 
multiple sclerosis: a double-blind, placebo-controlled, exploratory study. Journal 
of Neurology, Neurosurgery & Psychiatry 79:1027-1031 
Mullen Thomas D, Hannun Yusuf A, Obeid Lina M (2012) Ceramide synthases at the 
centre of sphingolipid metabolism and biology. Biochemical Journal 441:789-
802 
Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer 
pathogenesis and treatment. Nature Reviews Cancer 4:604-616 
Olitsky PK, Yager RH (1949) Experimental Disseminated Encephalomyelitis in White 
Mice. Journal of Experimental Medicine 90:213 
Pfeifenbring S, Nessler S, Wegner C, Stadelmann C, Bruck W (2015) Remyelination 
After Cuprizone-Induced Demyelination Is Accelerated in Juvenile Mice. Journal 
of Neuropathology and Experimental Neurology 74:756-766 
Phillip K. Peterson MT (2014) Neuroinflammation and Neurodegeneration ). 
Podbielska M, Krotkiewski H, Hogan EL (2012) Signaling and Regulatory Functions of 
Bioactive Sphingolipids as Therapeutic Targets in Multiple Sclerosis. 
Neurochemical Research 37:1154-1169 
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, 
Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, 
Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky 
JS (2011) Diagnostic criteria for multiple sclerosis: 2010 Revisions to the 
McDonald criteria. Annals of Neurology 69:292-302 
Ponnusamy S, Meyers-Needham M, Senkal CE, Saddoughi SA, Sentelle D, Selvam 
SP, Salas A, Ogretmen B (2010) Sphingolipids and cancer: ceramide and 
sphingosine-1-phosphate in the regulation of cell death and drug resistance. 
Future Oncology 6:1603-1624 
Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, Milanov I (2006) The 
epidemiology of multiple sclerosis in Europe. European Journal of Neurology 
13:700-722 
Ransohoff RM, Kivisäkk P, Kidd G (2003) Three or more routes for leukocyte migration 
into the central nervous system. Nature Reviews Immunology 3:569-581 
Mayo clinic, research and education (2014) AskMayoExpert. What is multiple 
sclerosis? . Rochester, Minn 
Rőszer T (2015) Understanding the Mysterious M2 Macrophage through Activation 
Markers and Effector Mechanisms. Mediators of Inflammation 2015:1-16 
Sphingolipids in MS 
 
77 
 
Sato F, Tanaka H, Hasanovic F, Tsunoda I (2011) Theiler's virus infection: 
Pathophysiology of demyelination and neurodegeneration. Pathophysiology 
18:31-41 
Schuchman EH, Levran O, Pereira LV, Desnick RJ (1992) Structural Organization and 
Complete Nucleotide-Sequence of the Gene Encoding Human Acid 
Sphingomyelinase (Smpd1). Genomics 12:197-205 
Skripuletz T, Hackstette D, Bauer K, Gudi V, Pul R, Voss E, Berger K, Kipp M, 
Baumgartner W, Stangel M (2012) Astrocytes regulate myelin clearance 
through recruitment of microglia during cuprizone-induced demyelination. Brain 
136:147-167 
Sospedra M, Martin R (2005) Immunology of Multiple Sclerosis. Annual Review of 
Immunology 23:683-747 
Stoffel B, Bauer P, Nix M, Deres K, Stoffel W (1998) Ceramide-independent CD28 and 
TCR signaling but reduced IL-2 secretion in T cells of acid sphingomyelinase-
deficient mice. European Journal of Immunology 28:874-880 
Syed A. Rizvi PKC (2011) Clinical Neuroimmunology; Multiple Sclerosis and related 
disorders  
Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, De Oliveira–Munding CC, 
van Heeckeren AM, Barr ML, von Kürthy G, Schmid KW, Weller M, Tümmler B, 
Lang F, Grassme H, Döring G, Gulbins E (2008) Ceramide accumulation 
mediates inflammation, cell death and infection susceptibility in cystic fibrosis. 
Nature Medicine 14:382-391 
Thannhauser S J RM (1940) Studies on animal lipids. XVI. the occurrence of 
sphingomyelin as a mixture of sphingomyelin fatty acid ester and free 
sphingomyelin, demonstrated by enzymatic hydrolysis and mild saponification.  
Rivers MD, et al., (1933) Observations on attempts to produce acute disseminated 
encephalomyelitis in monkeys 
Van Doorn R, Van Horssen J, Verzijl D, Witte M, Ronken E, Van Het Hof B, Lakeman 
K, Dijkstra CD, Van Der Valk P, Reijerkerk A, Alewijnse AE, Peters SLM, De 
Vries HE (2010) Sphingosine 1-phosphate receptor 1 and 3 are upregulated in 
multiple sclerosis lesions. Glia:n/a-n/a 
Wu YP, Mizugishi K, Bektas M, Sandhoff R, Proia RL (2008) Sphingosine kinase 1/S1P 
receptor signaling axis controls glial proliferation in mice with Sandhoff disease. 
Human Molecular Genetics 17:2257-2264 
Yu B, Zhou S, Wang Y, Qian T, Ding G, Ding F, Gu X (2012) miR-221 and miR-222 
promote Schwann cell proliferation and migration by targeting LASS2 after 
sciatic nerve injury. Journal of Cell Science 125:2675-2683 
Sphingolipids in MS 
 
78 
 
Yuan X-q, Qiu G, Liu X-j, Liu S, Wu Y, Wang X, Lu T (2012) Fluoxetine Promotes 
Remission in Acute Experimental Autoimmune Encephalomyelitis in Rats. 
Neuroimmunomodulation 19:201-208 
Zendedel A, Kashani IR, Azimzadeh M, Pasbakhsh P, Omidi N, Golestani A, Beyer C, 
Clarner T (2016) Regulatory effect of triiodothyronine on brain myelination and 
astrogliosis after cuprizone-induced demyelination in mice. Metabolic Brain 
Disease 31:425-433 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sphingolipids in MS 
 
79 
 
7 Publications 
 
Based on the PhD experimental work and the results reached using the cu-
prizone animal model, the following manuscript was published: 
 
• Chami M, Halmer R, Schnoeder L, Anne Becker K, Meier C, Fassbender 
K, et al. (2017) Acid sphingomyelinase deficiency enhances myelin 
repair after acute and chronic demyelination. PLoS ONE 12(6): 
e0178622. https://doi.org/10.1371/journal.pone.0178622 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sphingolipids in MS 
 
80 
 
8 Acknowledgements 
 
Foremost, I would like to thank my advisors PD. Dr. Silke Walter, Prof. Dr. Klaus 
Fassbender and Prof. Dr. Carola Meier for their outstanding support and guid-
ance in accomplishing my thesis. In particular, PD. Dr. Silke Walter was a 
unique driving force from the beginning till the end of my project.  I am heartily 
thankful to her, supervising my project with her enthusiasm and immense 
knowledge.  I am grateful for their motivation, patience and all the valuable dis-
cussions we had during my PhD years. I want to thank also Dr. Yang Liu for his 
help in technical and theoretical problems. 
I would like to thank my colleagues from AG Fassbender lab. Dr. Yann Decker, 
for all the discussions we had, the ideas we discussed and his supportive guid-
ance with his knowledge and experience. Ms. Andrea Schottek, Ms. Inge Tomic 
and Ms. Rebecca Lancaster provided skillful technical support from the start till 
the completion of my thesis. I would like to thank also Ms. Laura Schnoeder for 
being a great neighbor and also for the great talks we had whether scientific or 
not, delivering by that a friendly and enjoyable atmosphere in our office. A spe-
cial thanks also goes to Dr. Ramona Halmer, Dr. Sonja Gscheidle and Ms. Ani-
ko Kasztner.  
I would like to gratefully acknowledge the financial support for my thesis project 
from the German Research Foundation (DFG) and Novartis. 
Lastly, I owe my gratitude to my family for their understanding and support dur-
ing all these years. 
 
 
Sphingolipids in MS 
 
81 
 
Figures 
 
Figure 1:MRI abnormalities in relapsing–remitting multiple sclerosis. ............. 11 
Figure 2:Astrocytes orchestrate CNS inflammation. ........................................ 16 
Figure 3:Microglial activation as a continuous multistage process. ................. 18 
Figure 4:The sphingolipid signaling pathway . ................................................. 21 
Figure 5:Experimental animal models ............................................................. 13 
Figure 6:Weight measurments during chEAE.................................................. 33 
Figure 7:Representation of the corpus callosum. ............................................ 39 
Figure 8:Genetic Smpd1 deficiency prevents chEAE symtomps ..................... 47 
Figure 9:Genetic Smpd1 deficiency inhibits lymphocyte infiltration to the spinal 
cord. ................................................................................................................. 49 
Figure 10: Smpd1 deficiency significantly decreases astrogliosis and 
microgliosis in chEAE. ...................................................................................... 50 
Figure 11:Pharmacological inhibition of Asm significantly decreases chEAE 
symptoms and demyelination.. ......................................................................... 51 
Figure 12:Asm inhibition by amitriptyline stops T cell infiltration ...................... 52 
Figure 13:Brain sections with LFB and MBP.. ................................................. 54 
Figure 14 :Axonal damage analysis with IHC. ................................................. 56 
Figure 15:Effect of Asm -/- on astrogliosis and microgliois. .............................. 58 
Figure 16:Brain sections stained for LFB and MBP. ........................................ 59 
Figure 17:Stainings for APP and synaptophysin ............................................. 61 
Figure 18:Astrogliosis and microgliosis after amitriptyline treatment. .............. 62 
 
 
 
 
Sphingolipids in MS 
 
82 
 
Abbreviations 
 
ASM 
 
Acid sphingomyelinase 
Asm Acid sphingomyelinase (mouse) 
Smpd1 -/- Acid sphingomyelinase genetic knockout 
APC Antigen presenting cell 
APP Amyloid precursor protein 
ATP Adenosine triphosphate 
ANOVA One-way analysis of variance 
BBB Blood brain barrier 
BDNF Brain derived neurotrophic factor 
CC Corpus Callosum 
CD-3 Cluster of differentiation-3 
CD-4 Cluster of differentiation-4 
CD-8 Cluster of differentiation-8 
CFA Complete Freud’s Adjuvant 
chEAE chronic EAE 
CNS Central nervous system 
dH2O distilled water 
DNA Deoxyribonucleic acid 
EAE Experimental autoimmune encephalomyelitis 
EBV Epstein-Bar virus 
FGF-1 Fibroblast growth factor-1 
FGF-2 Fibroblast growth factor-2 
FIASMA Functional Inhibitor of Acid Sphingomyelinase 
GDNF Glial derived neurotrophic factor 
GFAP Glial fibrillary acidic protein 
GPCRs G-protein coupled receptors 
h Hour 
H2O2 Hydrogen peroxide 
HRP Horse radish peroxide 
Iba-1 Ionized calcium binding adapter-1   
IgG Immunoglobulin G 
IgM Immunoglobulin M 
Il-1β Interleukin-1betta 
Il-2 Interleukin-2 
Il-4 Interleukin-4 
Il-17 Interleukin-17 
IFNg Interferon-g 
IHC Immunohistochemistry 
i.p. Intraperitoneally 
i.v. Intravenously 
Sphingolipids in MS 
 
83 
 
KO/ko Knockout 
M Molar 
MBP Myelin Basic Protein 
Mrc-1 Mannose receptor-1 
MRI Magnetic resonance imaging 
MOG Myelin Oligodendrocyte Glycoprotein 
MS Multiple sclerosis 
NF-kb Nuclear factor – kappa b 
OPCs Oligodendrocyte Precursor cells  
Olig-2 Oligodendrocyte Transcription factor-2 
LFA-1 Lymphocyte function antigen-1 
LFB Luxol Fast Blue 
PA Periodic Acid 
PBS Phosphate buffer with salt 
PCR Polymerase chain reaction 
PFA Paraformaldehdye 
p.i. Post immunization 
PPMS Primary progressive multiple sclerosis 
RRMS Relapsing remitting multiple sclerosis 
RT Room temperature 
SD Standard deviation 
SEM Standard error of the mean 
SM Sphingomyelin 
Smpd-1 Sphingomyelin phosphodiesterase-1 gene 
SphK-1 Sphingosine Kinase-1 
SPMS Secondary progressive multiple sclerosis 
TBS Tris buffer with salt 
TBI Traumatic brain injury 
Treg T cell regulatory  
TGFb Transforming growth factorb 
TMEV Theiler’s Murine Encephalomyelitis virus 
TNF-α Tumor necrosis factor-alpha 
TLRs Toll-like receptors 
V Ventricles 
wks Weeks 
WT/wt Wild-type 
 
 
 
 
 
 
 
 
 
